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GERMLINE MUTATION DETECTION IN NEXT GENERATION 
SEQUENCING DATA AND TP53 MUTATION CARRIER PROBABILITY 
ESTIMATION FOR LI-FRAUMENI SYNDROME 
Gang Peng, B.S. 
Advisory Professor: Wenyi Wang, Ph.D. 
Next generation sequencing technology has been widely used in genomic analysis, but its 
application has been compromised by the missing true variants, especially when these variants are 
rare. We proposed a family-based variant calling method, FamSeq, integrating Mendelian 
transmission information with de novo mutation and sequencing data to improve the variant 
calling accuracy.  We investigated the factors impacting the improvement of family-based variant 
calling in simulation data and validated it in real sequencing data. In both simulation and real 
data, FamSeq works better than the single individual based method.  
In FamSeq, we implemented four different methods for the Mendelian genetic model to 
accommodate variations in data complexity. We parallelized the Bayesian network algorithm on 
an NVIDIA graphics processing unit to make the algorithm 10 times faster for relatively large 
families. Our simulation shows that Elston-Stewart algorithm performs the best when there is no 
loop in the pedigree. If there are loops, we recommend the Bayesian network method, which 
provides exact answers. 
The next generation sequencing technology has been developed over ten years. Many 
different sequencing platforms have been created to generate the sequencing data. Although all 
these platforms have their own strengths and weaknesses, people usually focus on one latest 
platform. Here we propose a method based on Bayesian hierarchical model to combine the 
sequencing data from multiple platforms. Our method was applied to both the simulation and real 
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data. The result showed that our method reduced the variant calling error rate comparing to single 
platform method.  
Besides the application of Mendelian transmission in sequencing data analysis, we also use it 
to estimate the TP53 mutation carrier probability for Li-Fraumeni syndrome (LFS). LFS is an 
autosomal dominant hereditary disorder. People with LFS have high risk of developing early 
onset cancers. We proposed LFSpro that is built on a Mendelian model and estimates TP53 
mutation probability, incorporating de novo mutation rates. With independent validation data 
from 765 families, we compared estimations using LFSpro versus classic LFS and Chompret 
clinical criteria. LFSpro outperformed Chompret and classic criteria in the pediatric sarcoma 
cohort and was comparable to Chompret criteria in the adult sarcoma cohort.  
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1. Introduction  
1.1 Background 
Next generation sequencing technology has been widely used in recent 10 years in different 
researching area1-5. Since the first next generation sequencing technology, Roche/454 system, was 
developed in 20056, many different kinds of sequencing technology have been developed, 
including ABI/SOLiD7, Illumina/Solexa8,9, Life Technology Ion Torrent10,11 and Pacific 
Biosciences PacBio12. A lot of next generation sequencing data is generated from these platforms. 
Figure 1.1: Illustration of variant calling process of DNA sequencing data.  
Although the methods for each platform to generate the sequencing data are quite different, 
all of them can produce a file including the sequencing reads information, such as a BAM file13. 
The analysis of sequencing data usually starts from these sequencing reads information files. 
There are two kinds of sequencing data, DNA sequencing data and RNA sequencing data. The 
processing of these two kinds of data is different. In this dissertation, we focus on variant calling 
process of the DNA sequencing data (Figure 1.1). In processing DNA sequencing data14-16, the 
reads are first mapped to a reference sequence. We search and mark the duplicated reads that are 
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usually removed from the following analysis to reduce the error rate. Indel realignment and base 
recalibration are followed to improve mapping accuracy and mapping quality calculation. After 
data cleanup, different methods are used to call the genotypes and indels. The called genotypes 
and indels are using in the evaluation step, such as phasing, association study and disease gene 
identification.  
In the second step of DNA sequencing data analysis, many different method are developing 
to calling the variant position including short oligonucleotide analysis package 2(SOAP2)17, 
sequencing alignment/map tools (Samtools)13, and genome analysis toolkit (GATK)14,15. These 
methods only consider the individuals are independent or assume they are in the same population 
without close relationship. When the individuals are from the same family, simple filtering the 
variants that are not followed the Mendelian transmission are adopted to reduce the false positive 
rate18. However, this method does not reduce the false negative rate and loses all the de novo 
mutations. A few studies showed that it reduced both false positive and false negative rate of 
variant calling by incorporating the family information19-21. We proposed a family-based variant 
calling method, FamSeq, integrating Mendelian transmission information with de novo mutation 
and sequencing data to improve the variant calling accuracy.  We investigated the factors 
impacting the improvement of family-based variant calling in simulation data, including family 
size, pedigree structure, minor allele frequency and coverage depth of sequencing to guide the 
design, analysis and interpretation of family-based sequencing analysis.  
There are three kinds of methods to implement family information into variant calling: 
Bayesian network algorithm22, Elston-Stewart algorithm23 and Markov chain Monte Carlo 
algorithm24,25. The Markov chain Monte Carlo method allows for uncertainty in the minor allele 
frequency estimation. The accuracy of Markov chain Monte Carlo method depends on the 
iteration times. It takes a long time for Markov chain Monte Carlo method to converge and the 
result is an approximation not an exact value. The Elston-Stewart algorithm has high speed and 
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exact result when there are no loops in the pedigree. However, when there are loops in the 
pedigree, looping-cutting method is required to cut the loops in the pedigree, which will increase 
the computing time substantially and give an approximate result that is not very close to the real 
one in some situation26, or adopting the method proposed by Cannings et al. that is very hard to 
implemented and requires much larger computing memory27. We can get the exact result from 
Bayesian network algorithm for pedigree with or without loops. However, the computing time for 
Bayesian network algorithm increases exponentially. It takes several days to processing the whole 
genome sequencing data for a family of over 10 individuals. We can hardly use this method when 
the family size is over 12. Most part of computing tasks in Bayesian network are homogeneous. It 
is easy to parallel these tasks into a GPU, which has hundreds of computing cores to calculate 
these tasks at the same time. After we implemented these algorithms into FamSeq, FamSeq were 
applied to pedigree sequencing data with different family structure and size that varied from 7 to 
12 to show the different performance of the four methods. 
The next generation sequencing technology has been developed about ten years28. Many 
different sequencing platforms have been created to generate the sequencing data28-30. All these 
platforms have their own strengths and weaknesses. The Illumina sequencing platform has high 
accuracy with short length of reads which cannot be used to get haplotype directly8,9,31, while the 
reads in PacBio platform could be over 1000bp to show the haplotype with high error rate12,31. 
The error type for each platform is different29,31. For a single platform, we may always make the 
same error even we control the data quality carefully and increase the read coverage. People 
usually focus on one platform without considering combing multiple platforms together to give a 
more reliable result. In the past 10 years, some platforms have faded away, such as Roach/454 
platform, there are many data generated by them remaining. Some individuals have been 
sequenced with many different platforms32, only the latest data is considered in most situation. It 
will save a lot of money if we can combine the data from these old platforms to generate the 
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result with comparable accuracy rate as the current platforms. Here we propose a method based 
on Bayesian hierarchical model to combine the sequencing data from multiple platforms to give a 
more accurate variant calling result than from a single platform. In simulation, we investigated 
the factors that might influence the accuracy of the model, including sample size, error rate, 
coverage depth, correlation between features and likelihood to show the guidelines for 
incorporating the multiple platforms together. We also collected the sequencing data of one 
sample from the two most popular sequencing platforms: MiSeq platform and Ion Torrent 
platform, to validate our method. 
Besides the application of Mendelian transmission in sequencing data analysis, we also use it 
in the risk prediction of Li-Fraumeni syndrome. Li-Fraumeni syndrome is an autosomal dominant 
hereditary disorder. People with LFS have high risk of developing early onset cancers33,34. For 
women the lifetime cancer risk is almost 100% because of breast cancer35. The main cause of Li-
Fraumeni syndrome is germline mutation in TP53 gene36. There are two commonly used clinical 
criteria: classic Li-Fraumeni syndrome criteria37 and Chompret criteria38,39. However, these two 
criteria only focus on the family members with disease without considering the healthy members. 
Much of the family information is discounted. In addition, the two criteria can only applied to the 
individual with cancers. It cannot estimate the probability of TP53 mutation for healthy 
individual. Given the cancer spectrum and onset in LFS and limitations of the clinical criteria, 
accurate identification of candidates for prospective TP53 mutation testing has been difficult. A 
more efficient prediction tool is needed for LFS identification, management and screening, which 
should ultimately decrease mortality. We proposed LFSpro that is built on a Mendelian risk 
prediction model40 and estimates TP53 mutation probability through the Elston-Stewart 
algorithm23, incorporating de novo mutation rates. We compared estimation using LFSpro ersus 
classic Li-Fraumeni syndrome criteria and Chompret criteria with independent validation data 
from 765 families (19,530 individuals in the United States [pediatric-onset sarcoma] and 
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Australia [adult-onset sarcoma]). LFSpro outperformed Chompret and classic criteria in the 
pediatric sarcoma cohort and was comparable to Chompret criteria in the adult sarcoma cohort. 
As the de novo mutation plays an important role in Li-Fraumeni syndrome41, we change the de 
novo mutation rate in the model to process the sensitivity analysis for the two data set. We 
developed and validated a clinically accessible tool that incorporates de novo mutation rates to 
accurately estimate TP53 mutation carriers. Family history of cancer evolves over time. LFSpro 
is sensitive to mutation carriers in families newly presenting in high-risk clinics, as well as those 
that we have followed for years. It is more broadly applicable than the clinical criteria. 
 
1.2 Dissertation Organization 
This dissertation focuses on two parts: germline mutation detection (variant calling) in next 
generation DNA sequencing data and TP53 mutation carrier probability estimation in families 
with Li-Fraumeni syndrome. In the first part, we developed two different methods. In the first 
method, we incorporated the pedigree information with Mendelian model to improve the variant 
calling accuracy. The second method is very different from the first one. We built a Bayesian 
hierarchical model combining the data from multiple platforms to reduce the error rate of 
germline mutation detection. In the second part, the family cancer history data instead of the next 
generation sequencing data is used to estimate the TP53 mutation carrier probability with 
Mendelian risk prediction model. Although the method used in the second part is similar to the 
first method in the first part, we decided to organize the dissertation according to the data type 
and purpose of the study for better fluency.  
Chapter 2 and 3 address the variant calling method with pedigree information. In Chapter 2, 
we introduced method of using family information to improve the variant calling accuracy. We 
investigated the factors that influence the method in simulation, including family size, pedigree 
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structure, minor allele frequency and coverage depth of sequencing to guide the design, analysis 
and interpretation of family-based sequencing analysis. We also applied FamSeq in the whole-
genome and target sequencing data analysis from 28 families. Both false positive rate and false 
negative rate are decreased using FamSeq comparing to the single individual based method. In 
Chapter 3, we described the details of four different methods implemented in FamSeq and 
compared these methods with different family size and structure. We focused on paralleling 
Bayesian network algorithm for family with loops when the pedigree size is relatively large, 
about 10 to 12 individuals in the family.  
In Chapter 4, we introduced the characteristics of different next generation sequencing 
platforms. Then we proposed a novel method with Bayesian hierarchical model to incorporate the 
data from multiple platforms. In simulation, we investigated the factors that might influence the 
accuracy of the model, including sample size, error rate, coverage depth, correlation between 
features and likelihood. Then we applied our method to next generation sequencing data of a 
1000 genome project42 sample NA12878 from two platforms: MiSeq platform and Ion Torrent 
platform. The result showed that our method reduced the variant calling error rate comparing to 
single platform method when the training sample size is not very small. 
TP53 mutation carrier probability estimation in families with Li-Fraumeni syndrome was 
introduced in Chapter 5. We gave an introduction about Li-Fraumeni syndrome at first. Then we 
described the Mendelian risk prediction model and our adaption of de novo mutation in the 
model. Our method was illustrated with some hypothetical families. We also compared our 
method with two clinical criteria with two real data sets.  
Finally, we concluded the dissertation discussed the future research in Chapter 6.  
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2. Germline Mutation Detection Using Family-based Sequencing Data 
This chapter is based upon the journal paper: Peng, G., Fan, Y., Palculict, T. B., Shen, P., 
Ruteshouser, E. C., Chi, A. K., Davis, R. W., Huff, V., Scharfe, C. & Wang, W. “Rare variant 
detection using family-based sequencing analysis”. Proceedings of the National Academy of 
Sciences of the United States of America 110, 3985-3990, doi:10.1073/pnas.1222158110 (2013). 
According to the journal policy, the author retains the right to include the published article in full 
or in part in a dissertation. 
2.1 Introduction 
Challenges in using whole-genome sequencing (WGS) data for identifying rare DNA variants 
responsible for heritable dis- ease include high false negative (FN) rates and the need to minimize 
the number of false positive (FP) variants to reduce the total number of variants for subsequent 
validation. Family-based sequencing designs have been applied to gene discovery for several 
diseases 2,43,44. Methods for calling variant positions in DNA sequence data include short 
oligonucleotide analysis package 2 (SOAP2)17, sequence alignment/map tools (Samtools)13, and 
genome analysis toolkit (GATK)14,15. When assessing data from related individuals, simple 
filtering can remove variants that do not conform to Mendelian transmission expectations, 
thereby reducing FPs. However, this approach does not reduce the frequency of FNs, and it 
removes all de novo mutations18. There are approaches that borrow information across 
neighboring variants through family-based haplotype phasing19,45. As an orthogonal approach, 
integrating Mendelian inheritance and raw data of family members at a single position can reduce 
both FPs and FNs and has been implemented in variant calling tools for family trios19,20. In recent 
simulation studies, Li et al.21 showed that joint variant calling in data from extended families will 
further improve detection of Mendelian variants and reduce FP de novo mutations. However, a 
limitation of their study is that simulations cannot incorporate many sources of variations that are 
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observed across millions of positions within a sample and across samples and families. Their 
study did not evaluate variant positions with base coverage greater than 40×, nor compare data 
generated by targeted versus WGS; they did not compare the performance of family-based calling 
for founder versus non- founder or for common versus rare variants. Thus, evaluation of a family-
integrated method under real settings across many individuals is required to prevent 
underestimation of its actual contributions to identifying rare variants in families. 
In addition, accurate variant calling and decreased FN rates (FNRs) enable the development 
of more efficacious and efficient studies that incorporate decisions about study design (who 
should be sequenced first in a large family and at what sequencing coverage), data analysis 
(setting up unknown parameters), and results interpretation (distinguishing true variants from FPs 
for functional association). Knowledge of factors contributing to accurate variant calling in 
families facilitates these decisions. 
We have developed a family-based variant calling program (Family-Based Sequencing 
Program, FamSeq) that provides a confidence measure for variant calls using data from all family 
members and builds on Bayesian networks and the Markov chain Monte Carlo (MCMC) 
algorithm25. We used this method to perform simulation studies and analyze sequencing data 
from 28 families [one from the HapMap (Haplotype Map) project, one with Wilms tumor (WT), 
and 26 with mitochondrial neuro-developmental disorders] presenting various pedigree structures. 
Compared with variant calling using a single-individual-based method or using only a family trio 
(14%), FamSeq reduced FN variant calls by 33% in the extended HapMap pedigree. In the 
analysis of actual data from one family, FamSeq resulted in the identification of an additional ∼300 to ∼1,200 new variant positions in WGS that otherwise would have been undetected using 
the Single method. 
Our goal is to provide a method for rare variant detection and to guide the design and analysis 
of a family-based sequencing study. We describe and validate our method, then describe 
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simulations and analyses of 92 samples from 28 families. We present a comprehensive 
investigation of factors that may determine the improvements achievable by our family-integrated 
method on a per-person and per-position basis. We also illustrate the effect of annotating 
Mendelian variants in studying either dominant or recessive traits. 
 
2.2 Method 
2.2.1 Individual-Based (Single) Method. Let Di denote the raw sequencing measurements—that 
is, read counts, read quality, and mapping quality— and Gi denote the genotype for sample i. For 
a family of n members, we use D to denote a vector !!; !!!; ! . . . ; !!!  and G a vector !!; !!!; ! . . . ; !!! . GATK provides likelihood estimates Pr(Di|Gi) in VCF files. By following 
Bayes’ rule, the genotype posterior probabilities are calculated as Pr(Di|Gi)  Pr(Di|Gi)Pr(Gi), 
where the prior Pr(Gi) is the expected genotype frequency in the population, and is calculated 
based on the MAF and Hardy-Weinberg equilibrium. 
 
2.2.2 Family-Based Method (FamSeq). Let P denote the pedigree structure. We calculate a 
genotype posterior probability Pr(Gi|P; D), which incorporates the actual pedigree structure and 
raw sequencing data and accommodates de novo mutations. We use three methods to compute 
Pr(Gi|P;D): a Bayesian network46, and Elston-Stewart and MCMC algorithms. FamSeq provides 
an updated VCF file that includes the family-based variant calling results and posterior 
probabilities. 
 
2.2.3 Full Simulation. To evaluate the contribution of family-based analysis to improving variant 
calling accuracy, we simulated all genotype configurations for a family trio and a family quartet. 
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First, we simulated the two parents’ genotypes at known MAFs. Then based on the parents’ 
genotypes, we simulated the children’s genotypes according to Mendelian transmission and 
allowing for de novo mutations. We then simulated likelihoods from the density functions of 
bivariate normal distributions for each genotype [where µ is equal to (1.7,1.7), (0,0), and (−1.7, 
−1.7) for the three genotypes, and Σ is equal to (0.3,0.15; 0.15,0.3) for homozygous and 
(0.45,0.225; 0.225,0.45) for heterozygous genotypes]. We performed this simulation using two 
settings: (i) MAF = 0.2, m = 1e-3, 10 million iterations, and (ii) MAF = 0.01, m = 1e−5, 100 
million iterations. We then calculated likelihoods Pr(Di|Gi) at the true µ’s and Σ* at (0.1,0.05; 
0.05,0.1). We used different variance matrices to account for additional technical effects that 
cannot be observed and estimated. 
 
2.2.4 Targeted Simulation. To evaluate the impact of pedigree size, structure, and MAF, we fixed 
the genotype configurations to extensions of (father = 0, mother = 0, child = 0) and (father = 0, 
mother = 1, child = 1), and simulated the raw intensity data based on bivariate normal 
distributions for each genotype. For pedigree size and structure, we considered the following 
scenarios: size = 2, parent–child pair; size = 3, family trio; size = 4, nuclear family with two 
children; size = 5, nuclear family with three children; size = 6, nuclear family with four children, 
or nuclear family with three children and one grandparent; and size = 7, two grandparents, two 
parents, and three children. For MAF, we considered 0.5, 0.2, 0.1, 0.05, 0.01, 1e−3, 1e−4, and 
1e−5. For each scenario, we repeated the simulation for 1 million times. There are two different 
groups, one for computing the FPRs and one for computing the FNRs. We computed the FPRs in 
individuals carrying homozygous references and computed the FNRs in individuals carrying 
heterozygous variants. When there is only one parent/grandparent, the parent/ grandparent is 1. 
When there are two parents/grandparents, one parent/ grandparent is 1 and the other is 0. 
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2.2.5 Whole Genome Sequencing Data. We downloaded the WGS data of NA12891, NA12892, 
and NA12878 from the 1000 Genomes Project (www.1000genomes.org), and NA12877 and 
NA12882 sequence data from the Sequence Read Archive (www.ncbi. nlm.nih.gov/Traces/sra). 
The data for the first three samples are generated using GAII and those for the other two are 
generated using HiSeq2000. We downloaded the consistent calls from the HapMap Phase II and 
III merged genotype data for NA12891, NA12892, and NA12878 (http://hapmap.ncbi. 
nlm.nih.gov). Using HiSeq2000, we also conducted WGS of five samples (one trio plus two 
distant relatives) from a large pedigree that presented with Wilms tumor. Our analysis focused on 
a 5.6 MB linkage region in Chr19q. In WGS analysis, we filtered out bases that are noted as 
simple repeats or segmental duplications by the University of California, Santa Cruz human 
genome assembly hg19, and those with total allelic counts less than 10. 
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Table 2.1 Summary of target sequencing data from 26 families. (Table reprint from Peng, G. et al 
PNAS, 2013) 
 
 
 
!!
Table S2. Summary of family sequencing data.
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2.2.6 Target Sequencing Data. We performed DNA sequence capture of 524 nuclear-encoded 
mitochondrial genes47 from 92 samples in 26 families (Table 2.1) and multiplex-sequenced all 
capture libraries using Illumina HiSeq2000, except for MTF04-b, c, and d, which were sequenced 
using MiSeq. Our analysis focused on a 762 KB region of autosomes. 
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2.2.7 Methods Evaluation. We calculated the FNR as the rate of reference or no calls for a true 
variant genotype, and the FPR as the rate of variant calls for a reference genotype. We defined 
concordance as having genotype calls that are identical to the HapMap truth, and discordance as 
having genotype calls that are different from the HapMap truth. 
 
2.2.8 Unique Variant Calls of FamSeq and the Single Method. We combined the posterior 
probability of the heterozygous variant with that of the homozygous variant to evaluate the 
number of unique variant calls added by either FamSeq or the Single method. We designated a 
call as a unique variant call if the method of interest changes the calls from those of the 
alternative method in the following ways: reference to variant, no call to variant, or reference to 
no call.  
 
2.3 Results 
2.3.1 FamSeq. Figure 2.1 describes the FamSeq framework. This method provides a confidence 
measure for genotype calls, which is a posterior probability Pr(Gi|D, P). Here G denotes 
genotype, i denotes an individual, P denotes pedigree structure, and D is a vector that denotes 
sequencing data, including read counts, base quality, and mapping quality, for all n family 
members (individual i and relatives). Incorporating data from family members, Pr(Gi|D, P) allows 
for accurate variant calling when the data from person i are not informative, perhaps due to a 
weak signal-to- noise-ratio, by borrowing strength from all relatives (Figure. 1B). Here we 
measure the signal-to-noise-ratio using the ratios of the likelihood estimates (Pr(Di|Gi)) for the 
two most likely genotypes. FamSeq has included probabilities of de novo mutations. It allows for 
variable pedigree size (n > 3) and structure. In addition to using the Elston-Stewart algorithm as 
in Li et al.21 for pedigree analysis, we implemented two unique approaches, Bayesian network 
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and MCMC. The Bayesian network approach directly calculates joint probabilities for each 
combination of genotypes of all family members and allows for analytic calculation in pedigrees 
with marriage loops and/or consanguinity, as long as they form directed acyclic graphs. This 
method gives faster computation than the Elston-Stewart algorithm with or without loops in 
pedigrees of size less than 7. The MCMC method allows for the use of continuous probability 
density functions as priors on the genotype probability Pr(Gi) and likelihood Pr(Di|Gi), instead of 
designating the point mass a priori. 
Figure 2.1 Illustration of variant calling using FamSeq. (A) FamSeq variant calling framework. 
(B) Two examples in a family trio. We use 0 to denote reference and 1 to denote heterozygous 
variant. The order of genotypes presented in the parentheses is father, mother, and child. In both 
cases, FamSeq gives the child a high posterior probability (>0.9) for the true genotype even when 
the child has a relatively low log10 LLR. This is done in FamSeq by borrowing strength from 
data of the parents. (Figure reprint from Peng, G. et al PNAS, 2013) 
Figure 2.2 A family with Wilms tumor for genomic sequencing of 19q13-linked region. The 
family trio is affected mother (WTX524-004), unaffected father (WTX524-029), and affected 
child (WTX524-709). Two affected distant rela- tives (WTX524-708, WTX524-000) are also 
sequenced. (Figure reprint from Peng, G. et al PNAS, 2013) 
quality, and mapping quality, for all n family members (individual
i and relatives). Incorporating data from family members,
Pr(GijD,P) allows for accurate variant calling when the data from
person i a e not i formative, perhaps due to a weak signal-to-
noise-ratio, by borrowing strength from all relatives (Fig. 1B).
Here we measure the signal-to-noise-ratio using the ratios of the
likelihood estimates (Pr(DijGi)) for the twomost likely genotypes.
FamSeq has included probabilities of de novo mutations. It allows
for variable pedigree size (n > 3) and structure. In addition to
using the Elston-Stewart algorithm as in Li et al. (12) for pedigree
analysis, we implemented two unique approaches, Bayesian net-
work and MCMC. The Bayesian network approach directly cal-
culates joint probabilities for each combination of genotypes of
all family members and allows for analytic calculation in pedi-
grees with marriage loops and/or consanguinity, as long as they
form directed acyclic graphs. This method gives faster computa-
tion than the Elston-Stewart algorithm with or without loops in
pedigrees of size less than 7. The MCMC method allows for the
use of continuous probability density functions as priors on the
genotype probability PrðGiÞ and likelihood PrðDijGiÞ, instead of
designating the point mass a priori.
Motivating Example: Family with Inherited WT. Familial transmis-
sion of predisposition to WT, a childhood kidney tumor, is con-
sistent with an autosomal dominant mutation with incomplete
penetrance. Two predisposition genes have been localized by
genetic linkage studies, but neither gene has been id ntiﬁed (15).
We generated WGS data for ﬁve members of a large WT family
and focused on a 5.6 MB linkage region on chr19q. Because
genetic linkage has been previously demonstrated, the two dis-
tantly related individuals WTX524-708 and WTX524-000 are
expected to share the same Mendelian variants as individuals
WTX524-709 and WTX524-004 in the trio (Fig. 2). Comparing
FamSeq with GATK (with variant recalibration), we found that
both methods identiﬁed 4,920 positions with variant calls in all
four affected family members. FamSeq identiﬁed an additional
132 positions and GATK uniquely identiﬁed one position.
Sanger Validation. To assess the validity of the FamSeq uniquely
called variants, we performed Sanger sequencing on 57 of the
132 positions, which exist in a subregion and meet an additional
requirement of presenting reference calls in the unaffected fa-
ther. This four-variants-plus-one-reference ﬁltering procedure is
designed to prioritize variants potentially important for WT and
was performed on both FamSeq and GATK-based calls. We
obtained reliable Sanger results on 38 FamSeq-unique positions
and conﬁrmed that 32 (61 variant calls) are true (SI Appendix,
Table S1). Our validation rate is 61/73 = 84% (95% conﬁdence
interval: 75–92%). Among the conﬁrmed FamSeq-unique var-
iants, 17 (53%) are rare (not reported or at a minor allele
frequency of less than 5%). Other than one position where
FamSeq corrected a call from the variant by GATK to reference
in the unaffected father, the FamSeq-unique positions were
missed by GATK because they were (i) called as reference in one
affected individual, (ii) removed during variant quality score
recalibration, or (iii) had variant calls at a tranche level of 99.9–
100 or lower.
Using simulated and actual data, we identiﬁed variables that
determine the possible improvements from using our family-based
analysis. From here on, we compare FamSeq with the Single
method based on their posterior probabilities. First, we describe
the results based on simulations.
Genotype Conﬁgurations. FamSeq improved the accuracy in all
Mendelian genotypes (15 scenarios for a family trio, Fig. 3A) and
made substantial improvements in two scenarios: (i) at positions
where all family members have reference genotypes, FamSeq
corrected FP calls (∼30%; SI Appendix, Fig. S1), and (ii) at
positions where a single parent and child carry heterozygous
variants, FamSeq corrected FN calls (20–40%; SI Appendix, Fig.
S1). FamSeq identiﬁed true Mendelian positions that were er-
roneously called as variants by the Single method, as shown by
the red cells in the heatmap of Fig. 3A. For example, at truth = 000,
FamSeq reduced discordant calls of 001; at truth = 101, again
FamSeq reduced discordant calls of 001 and 102, made by the
Single method. When the de novo mutation rate is high [1 × 10−5,
compared with variants with minor allele frequency (MAF) of
0.01; SI Appendix, Fig. S1B], FamSeq missed 34% of true de novo
mutations correctly called by the Single method, suggesting
possible underestimations. We made similar observations with a
family quartet.
MAF. The MAF parameter is used for computing prior probabil-
ities of genotypes, Pr(G), in FamSeq and the Single method and is
mostly unknown (Fig. 3B). Setting different values of MAF (from
10−5 to 0.5) switches the balance between the FNR and FPR in
the Single method. As MAF increases, FNRs decrease and FPRs
increase. With FamSeq, not only are both error rates lower at all
values, but as the MAF varies, the changes in FNRs and in FPRs
in the children, and changes in FNRs in the parents, are much
attenuated; that is, error rates are less dependent onMAF values.
Therefore, by jointly calling variants in all family members, we can
set the sameMAF at all base positions, for example 0.001, without
compromising the detection of true variants.
Family Size and Pedigree Structure. Starting from a parent–child
pair, FamSeq reduced both FNR and FPR when we included the
second parent (family size = 2 to size = 3), and then added
another sibling (size = 3, 4) (Fig. 3C). Interestingly, adding more
children (size = 4, 5, 6) did not further reduce error rates,
whereas adding the grandparents (size = 5–7) made additional
reductions in both FNR and FPR. When the parental data are
A B Fig. 1. Illustration of variant calling using Fam-Seq. (A) FamSeqvariantcallingframework. (B)Two
examples in a family trio. We use 0 to denote ref-
erence and 1 to denote heterozygous variant. The
orderofgenotypespresented in theparentheses is
father, mother, and child. In both cases, FamSeq
gives the child a high posterior probability (>0.9)
for the true genotype even when the child has
a relatively low log10 LLR. This is done in FamSeq
by borrowing strength from data of the parents.
WTX524 
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Fig. 2. A family with Wilms tumor for genomic sequencing of 19q13-linked
region. The family trio is affected mother (WTX524-004), unaffected father
(WTX524-029), and affected child (WTX524-709). Two affected distant rela-
tives (WTX524-708, WTX524-000) are also sequenced.
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quality, and mapping quality, for all n family members (individual
i and relatives). Incorporating data from family members,
Pr(GijD,P) allows for accurate variant calling when the data from
person i are not informative, perhaps due to a weak signal-to-
noise-ratio, by borrowing strength from all relatives (Fig. 1B).
Here we measure the signal-to-noise-ratio using the ratios of the
likelihood estimates (Pr(DijGi)) for the twomost likely genotypes.
FamSeq has included probabilities of de novo mutations. It allows
for variable pedigree size (n > 3) and structure. In addition to
using the Elston-Stewart algorithm as in Li et al. (12) for ped gree
analysis, we implemented two unique approaches, Bayesian net-
work and MCMC. The Bayesian network approach directly cal-
culates joint probabilities for each combination of genotypes of
all family members and allows for analytic calculation in pedi-
grees with marriage loops and/or consanguinity, as long as they
form directed acyclic graphs. This method gives faster computa-
tion than the Elston-Stewart algorithm with or without loops in
pedigrees of size less than 7. The MCMC method allows for the
use of continuous probability density functions as priors on the
genotype probability PrðGiÞ and likelihood PrðDijGiÞ, instead of
designating the point mass a priori.
Motivating Example: Family with Inherited WT. Familial transmis-
sion of predisposition to WT, a childhood kidney tumor, is con-
sistent with an autosomal dominant mutation with incomplete
penetrance. Two predisposition genes have been localized by
genetic linkage studies, but neither gene has been identiﬁed (15).
We generated WGS data for ﬁve members of a large WT family
and focused on a 5.6 MB linkage region on chr19q. Because
genetic linkage has been previously demonstrated, th two dis-
tantly related individuals WTX524-708 and WTX524-000 are
expected to share the same Mendelian variants as individuals
WTX524-709 and WTX524-004 in the trio (Fig. 2). Comparing
FamSeq with GATK (with variant recalibration), we found that
both methods identiﬁed 4,920 positions with variant calls in all
four affected family members. FamSeq identiﬁed an additional
132 positions and GATK uniquely identiﬁed one position.
Sanger Validation. To assess the validity of the FamSeq uniquely
called variants, we performed Sanger sequencing on 57 of the
132 positions, which exist in a subregion and meet an additional
requirement of presenting reference calls in the unaffected fa-
ther. This four-variants-plus-one-reference ﬁltering procedure is
designed to prioritize variants potentially important for WT and
was performed on both FamSeq and GATK-based calls. We
obtained reliable Sanger results on 38 FamSeq-unique positions
and conﬁrmed that 32 (61 variant calls) are true (SI Appendix,
Table S1). Our validation rate is 61/73 = 84% (95% conﬁdence
interval: 75–92%). Among the conﬁrmed FamSeq-unique var-
iants, 17 (53%) are rare (not reported or at a minor allele
frequency of less than 5%). Other than one position where
FamSeq corrected a call from the variant by GATK to reference
in the unaffected father, the FamSeq-unique positions were
missed by GATK because they were (i) called as reference in one
affected individual, (ii) removed during variant quality score
recalibration, or (iii) had variant calls at a tranche level of 99.9–
100 or lower.
Using simulated and actual data, we identiﬁed variables that
determine the possible improvements from using our family-based
analysis. From here on, we compare FamSeq with the Single
method b sed on their posterior probabilities. First, we des ribe
the results based on simulations.
Genotype Conﬁgurations. FamSeq improved the accuracy in all
Mendelian genotypes (15 scenarios for a family trio, Fig. 3A) and
made substantial improvements in two scenarios: (i) at positions
where all family members have reference genotypes, FamSeq
corrected FP calls (∼30%; SI Appendix, Fig. S1), and (ii) at
positions where a single parent and child carry h terozygous
variants, FamSeq corrected FN calls (20–40%; SI Appendix, Fig.
S1). FamSeq identiﬁed true Mendelian positions that were er-
roneously called as variants by the Single method, as shown by
the red cells in the heatmap of Fig. 3A. For example, at truth = 000,
FamSeq reduced discordant calls of 001; at truth = 101, again
FamSeq reduced discordant calls of 001 and 102, made by the
Single method. When the de novo mutation rate is high [1 × 10−5,
compared with variants with minor allele frequency (MAF) of
0.01; SI Appendix, Fig. S1B], FamSeq missed 34% of true de novo
mutations correctly called by the Single method, suggesting
possible underestimations. We made similar observations with a
family quartet.
MAF. The MAF parameter is used for computing prior probabil-
ities of genotypes, Pr(G), in FamSeq and the Single method and is
mostly unknown (Fig. 3B). Setting different values of MAF (from
10−5 to 0.5) switches the balance between the FNR and FPR in
the Single method. As MAF increases, FNRs decrease and FPRs
increase. With FamSeq, not only are both error rates lower at all
values, but as the MAF varies, the changes n FNRs and in FPRs
in the children, and changes in FNRs in the parents, are much
attenu ted; that is, error rates are less dependent onMAF values.
Therefore, by jointly calling variants in all family members, we can
set the sameMAF at all base positions, for example 0.001, without
compromising the detection of true variants.
Family Size and Pedigree Structure. Starting from a parent–child
pair, FamSeq reduced both FNR and FPR when we included the
second parent (family size = 2 to size = 3), and then added
another sibling (size = 3, 4) (Fig. 3C). Interestingly, adding more
children (size = 4, 5, 6) did not further reduce error rates,
whereas adding the grandparents (size = 5–7) made additional
reductions in both FNR and FPR. When the parental data are
A B Fig. 1. Illustration of variant calling using Fam-Seq. (A) FamSeqvariantcallingframework. (B)Two
examples in a family trio. We use 0 to denote ref-
erence and 1 to denote heterozygous variant. The
orderofgenotypespresented in theparentheses is
father, mother, and child. In both cases, FamSeq
gives the child a high posterior probability (>0.9)
for the true genotype even when the child has
a relatively low log10 LLR. This is done in FamSeq
by borrowing strength from data of the parents.
WTX524 
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708 
008 007 006 
709 729 728 
029 005 003 002 001 068 009 
100 200 
300 350 
103 132 101 201 
Unilateral tumor Bilateral tumor Obligate carrier 
Fig. 2. A family with Wilms tumor for genomic sequencing of 19q13-linked
region. The family trio is affected mother (WTX524-004), unaffected father
(WTX524-029), and affected child (WTX524-709). Two affected distant rela-
tives (WTX524-708, WTX524-000) are also sequenced.
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2.3.2 Motivating Example: Family with Inherited Wilms Tumor. Familial transmission of 
predisposition to WT, a childhood kidney tumor, is consistent with an autosomal dominant 
mutation with incomplete penetrance. Two predisposition genes have been localized by genetic 
linkage studies, but neither gene has been identified48. We generated WGS data for five members 
of a large WT family and focused on a 5.6 MB linkage region on chr19q. Because genetic linkage 
has been previously demonstrated, the two distantly related individuals WTX524-708 and 
WTX524-000 are expected to share the same Mendelian variants as individuals WTX524-709 
and WTX524-004 in the trio (Figure. 2.2). Comparing FamSeq with GATK (with variant 
recalibration), we found that both methods identified 4,920 positions with variant calls in all four 
affected family members. FamSeq identified an additional 132 positions and GATK uniquely 
identified one position. 
Table 2.2 Sanger verification on FamSeq-unique positions. These positions were found to have 
variant genotypes in all four affected relatives and a reference genotype in the unaffected spouse. 
There are 38 positions in total and 32 positions were confirmed by Sanger sequencing (84%, p-
value<0.0001). The false positive positions are listed at the bottom of the table. (Table reprint 
from Peng, G. et al PNAS, 2013) 
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2.3.3 Sanger Validation. To assess the validity of the FamSeq uniquely called variants, we 
performed Sanger sequencing on 57 of the 132 positions, which exist in a subregion and meet an 
additional requirement of presenting reference calls in the unaffected father. This four-variants-
plus-one-reference filtering procedure is designed to prioritize variants potentially important for 
WT and was performed on both FamSeq and GATK-based calls. We obtained reliable Sanger 
results on 38 FamSeq-unique positions and confirmed that 32 (61 variant calls) are true (Table 
2.2). Our validation rate is 61/73 = 84% (95% confidence interval: 75–92%). Among the 
confirmed FamSeq-unique variants, 17 (53%) are rare (not reported or at a minor allele frequency 
of less than 5%). Other than one position where FamSeq corrected a call from the variant by 
GATK to reference in the unaffected father, the FamSeq-unique positions were missed by GATK 
because they were (i) called as reference in one affected individual, (ii) removed during variant 
quality score recalibration, or (iii) had variant calls at a tranche level of 99.9– 100 or lower. 
Using simulated and actual data, we identified variables that determine the possible 
improvements from using our family-based analysis. From here on, we compare FamSeq with the 
Single method based on their posterior probabilities. First, we describe the results based on 
simulations. 
 
2.3.4 Genotype Configurations. FamSeq improved the accuracy in all Mendelian genotypes (15 
scenarios for a family trio, Figure 2.3A) and made substantial improvements in two scenarios: (i) 
at positions where all family members have reference genotypes, FamSeq corrected FP calls 
(∼30%;  Figure 2.4), and (ii) at positions where a single parent and child carry heterozygous 
variants, FamSeq corrected FN calls (20–40%; Figure 2.4). FamSeq identified true Mendelian 
positions that were erroneously called as variants by the Single method, as shown by the red cells 
in the heatmap of Fig. 2.3A. For example, at truth = 000, FamSeq reduced discordant calls of 
001; at truth = 101, again FamSeq reduced discordant calls of 001 and 102, made by the Single 
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method. When the de novo mutation rate is high [1 × 10−5, compared with variants with minor 
allele frequency (MAF) of 0.01; Figure 2.4B], FamSeq missed 34% of true de novo mutations 
correctly called by the Single method, suggesting possible underestimations. We made similar 
observations with a family quartet. 
Figure 2.3 Simulation results. (A) Highlighted results from a full simulation of all possible 
genotype configurations of a family. Each row is the simulated genotype for the family trio 
(father, mother, child). Here, 0 is homozygous reference, 1 is heterozygous variant, and 2 is 
homozygous variant. Each heatmap entry is the percent reduction in discordance from using the 
Single method to using FamSeq. The values on the diagonal are equal to the sum of all other 63 
values in the same row. Only 27 columns are shown. Additionally, there are 37 columns with 
genotypes containing “no calls.” The corresponding complete results can be found in Figure 2.4. 
The barplot on the right presents the frequency for observing each configuration. (B) Targeted 
simulation to evaluate effect of MAF. F stands for FamSeq and S stands for single method. (C) 
Targeted simulation to evaluate effect of pedigree size and structure. (Figure reprint from Peng, 
G. et al PNAS, 2013) 
not available, we also observed improvements made by FamSeq
in analyzing all siblings together (size = 3, FNR 23.5% vs. 13.3%,
FPR 0.5% vs. 0.4%). This has important implications when
prioritizing individuals from a larger pedigree to accurately and
comprehensively detect rare DNA variants.
Contribution to Family Members. The reduction in error rates using
FamSeq is membership-dependent (Fig. 3 B and C). FNRs are
better controlled in parents than in children. FPRs are better
controlled in children than in parents (founders), which reduces
the cost of subsequent sequence veriﬁcations. Both reduce the
FPs in calling de ovo mutatio s in children. Accordingly, when
grandparents’ data are available, the FPRs in the corresponding
parent (nonfounder) decrease substantially, which improves the
det ction of de novo mutations in children.
Next, we present results from the analysis of sequencing data
in extended families (SI Appendix, Table S2).
WGS Data Analysis. We analyzed a three-generation HapMap
WGS dataset of ﬁve samples. In the whole genomes of HapMap
samples, FamSeq found 1,179, 317, and 494 new variant positions
across all samples when analyzing pedigrees g3 (grandparent trio),
c3 (child trio), and a5 (all ﬁve).Within each sample, FamSeq called
∼7,000 to ∼32,000 more variants than the Single method. Samples
with lower coverage (NA12892 at ∼25×; SI Appendix, Tables S2
and S3) beneﬁted most from FamSeq analysis, exhibiting a greater
percentage of increased variant calls.
HapMap Sample Validation. In three samples (mean coverage ∼25–
30×), we compared FamSeq calls with HapMap calls at ∼1
million single-nucleotide polymorphism (SNP) positions (16) (SI
Appendix, Table S3). Homozygous genotypes are more easily
identiﬁed than heterozygous variants (17). Using known SNP
data, we combined all homozygous SNP positions as true neg-
atives and used all heterozygous SNP positions as true positives,
from NA12878, NA12891, and NA12892 (∼400,000 true pos-
itives for each sample). As expected, FamSeq called more posi-
tions at high conﬁdence (7–29% fewer no call positions) and
identiﬁed more true variants with percent reduction in FNs of
14–33%, and without substantially increasing the number of false
discoveries (1–3%; Fig. 4A and SI Appendix, Table S3). In par-
ticular, comparing pedigrees c3 and a5, we observed a statisti-
cally signiﬁcant difference in the percent reduction of FNs (15%
vs. 33% in NA12878, P < 0.0001). This result is consistent with
simulations comparing sizes of 5 and 7 in the parent (Fig. 3C).
We also observed low sensitivity to varying MAF values in var-
iant calling when using FamSeq (SI Appendix, Fig. S2). In con-
trast to the simulations, we did not observe a decrease in FPs in
the child (NA12878 in g3). One explanation is we derived the
input likelihood estimates from GATK, which may aggressively
ﬁlter out FPs, but at a price of missing some true positives.
This validation was performed at HapMap SNP positions,
including all common SNPs whose known genotypes may have
been used for calibration by GATK. Additionally, most of these
SNPs (98%) are located in the noncoding region. Therefore, we
look for larger improvements from using FamSeq for ﬁnding rare
DNA variants at equen e sites where variant calling in the
Single method has not been optimized.
Targeted Sequencing Data Analysis in Families with Mitochondrial
Neurodevelopmental Disorders. These families vary in size from 2
to 7 and include single-parent, nuclear, as well as three-generation
families (SI Appendix, T ble S2). In each individual, we sequenced
524 nuclear-encoded mitochondrial candidate genes (18, 19) and
focused our analysis on 962 Kb of coding regions in autosomes.
We observed a signiﬁcant increase in new variants called by
FamSeq in the parents (Fig. 4B and SI Appendix, Table S4;
FamSeq vs. Single method at size = 3: Kolmogorov-Smirnov test
P < 0.001; FamSeq vs. Single method at size = 4: P < 0.001;
FamSeq at size = 3 vs. size = 4: P < 0.001, FamSeq at size = 4 vs.
size > 4, P = 0.06). We measured the signiﬁcantly increased
number of variants as related to family size in a total of 45 indi-
viduals from 25 different families, thus accounting for biological
and technological variations between different sequenced indi-
viduals. We are currently validating these positions using Sanger-
based sequencing, which may facilitate ﬁnding the unknown gene
defects in these families. We did not observe signiﬁcant increases
in variants in the children (Fig. 3C and SI Appendix, Fig. S3).
However, the approximate reduction in FNRs (estimated by %
FamSeq-unique variants) in the three-generation pedigree was 1–
5%, which is substantially larger than the 0.1% observed at HapMap
SNP positions (SI Appendix, Table S5) indicating the power of
FamSeq in detecting rare variants. In three of these families, we
found 15 unique variant positions (SI Appendix, Table S5) that are
not reported in the Single Nucleotide Polymorphism Database
(dbSNP) or the 1,000 Genomes Project, nine of which are non-
synonymous. We also analyzed family MTF04 in three ways: trio,
trio plus either pair of grandparents, and trio plus both pairs of
grandparents. Interestingly, compared with the Single method for
this family, only the extended pedigree (size = 5 or 7) analysis
A B C
Fig. 3. Simulation results. (A) Highlighted results from a full simulation of all possible genotype conﬁgurations of a family. Each row is the simulated
genotype for the family trio (father, mother, child). Here, 0 is homozygous reference, 1 is heterozygous variant, and 2 is homozygous variant. Each heatmap
entry is the percent reduction in discordance from using the Single method to using FamSeq. The values on the diagonal are equal to the sum of all other 63
values in the same row. Only 27 columns are shown. Additionally, there are 37 columns with genotypes containing “no calls.” The corresponding complete
results can be found in SI Appendix, Fig. S1. The barplot on the right presents the frequency for observing each conﬁguration. (B) Targeted simulation to
evaluate effect of MAF. F stands for FamSeq and S stands for single method. (C) Targeted simulation to evaluate effect of pedigree size and structure.
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Figure 2.4 Simulations for all possible genotype configurations in a family trio. In the heatmap 
each row is the simulated genotype for the family trio (father, mother, child). Here, 0 is 
homozygous reference, 1 is heterozygous variant; 2 is homozygous variant, and N is no call. Each 
heatmap entry is the percent reduction in discordance from using the Single method to using 
FamSeq. Red suggests improvement and blue suggests otherwise. The barplot on the right 
presents the frequency for observing each configuration. The percentage improvement out of all 
counts of truth for FamSeq within each configuration is shown in the following table. A) We 
simulated 10 million iterations for family trios at MAF=0.2 and de novo mutation rate=1e-3. B) 
We simulated 100 million iterations for family trios at MAF=0.01 and de novo mutation rate=1e-
5. We could not observe some rare configurations. The table gives percentage improvement for 
FamSeq within each configuration. (Figure reprint from Peng, G. et al PNAS, 2013) 
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2.3.5 Minor Allele Frequency. The MAF parameter is used for computing prior probabilities of 
genotypes, Pr(G), in FamSeq and the Single method and is mostly unknown (Fig. 2.3B). Setting 
different values of MAF (from 10−5 to 0.5) switches the balance between the FNR and FPR in 
the Single method. As MAF increases, FNRs decrease and FPRs increase. With FamSeq, not only 
are both error rates lower at all values, but as the MAF varies, the changes in FNRs and in FPRs 
in the children, and changes in FNRs in the parents, are much attenuated; that is, error rates are 
less dependent on MAF values. Therefore, by jointly calling variants in all family members, we 
can set the same MAF at all base positions, for example 0.001, without compromising the 
detection of true variants. 
 
2.3.6 Family Size and Pedigree Structure. Starting from a parent–child pair, FamSeq reduced 
both FNR and FPR when we included the second parent (family size = 2 to size = 3), and then 
added another sibling (size = 3, 4) (Figure. 2.3C). Interestingly, adding more children (size = 4, 5, 
6) did not further reduce error rates, whereas adding the grandparents (size = 5–7) made 
additional reductions in both FNR and FPR. When the parental data are not available, we also 
observed improvements made by FamSeq in analyzing all siblings together (size = 3, FNR 23.5% 
vs. 13.3%, FPR 0.5% vs. 0.4%). This has important implications when prioritizing individuals 
from a larger pedigree to accurately and comprehensively detect rare DNA variants. 
 
2.3.7 Contribution to Family Members. The reduction in error rates using FamSeq is 
membership-dependent (Fig. 2.3 B and C). FNRs are better controlled in parents than in children. 
FPRs are better controlled in children than in parents (founders), which reduces the cost of 
subsequent sequence verifications. Both reduce the FPs in calling de novo mutations in children. 
Accordingly, when grandparents’ data are available, the FPRs in the corresponding parent 
! ! 21 
(nonfounder) decrease substantially, which improves the detection of de novo mutations in 
children. 
 
2.3.8 Whole Genome Sequencing Data Analysis. We analyzed a three-generation HapMap WGS 
dataset of five samples. In the whole genomes of HapMap samples, FamSeq found 1,179,317, 
and 494 new variant positions across all samples when analyzing pedigrees g3 (grandparent trio), 
c3 (child trio), and a5 (all five). Within each sample, FamSeq called ∼7,000 to ∼32,000 more 
variants than the Single method. Samples with lower coverage (NA12892 at ∼25×; Table 2.3) 
benefited most from FamSeq analysis, exhibiting a greater percentage of increased variant calls. 
Table 2.3 Summary of validation results using HapMap SNPs. The results are based on three 
HapMap samples NA12891, NA12892 and NA12878. A) Known SNPs called consistently from 
HapMap Phase II and III. B) Concordance and error rates for FamSeq as compared to the Single 
(individual-based) method. The SNP calls for these three individuals are provided by the HapMap 
project and used as truth. FamSeq is run on subsets of the family, g3 and c3, and on the entire 
family, a5. NR = no call rate; FPR = false positive rate; FDR = false discovery rate. (Table 
reprint from Peng, G. et al PNAS, 2013) 
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2.3.9 HapMap Sample Validation. In three samples (mean coverage ∼25– 30×), we compared 
FamSeq calls with HapMap calls at ∼1 million single-nucleotide polymorphism (SNP) positions49 
(Table 2.3). Homozygous genotypes are more easily identified than heterozygous variants50. 
Using known SNP data, we combined all homozygous SNP positions as true negatives and used 
all heterozygous SNP positions as true positives, from NA12878, NA12891, and NA12892 
(∼400,000 true positives for each sample). As expected, FamSeq called more positions at high 
confidence (7–29% fewer no call positions) and identified more true variants with percent 
reduction in FNs of 14–33%, and without substantially increasing the number of false discoveries 
(1–3%; Figure 2.5A and Table 2.3). In particular, comparing pedigrees c3 and a5, we observed a 
statistically significant difference in the percent reduction of FNs (15% vs. 33% in NA12878, P < 
0.0001). This result is consistent with simulations comparing sizes of 5 and 7 in the parent 
(Figure 2.3C). We also observed low sensitivity to varying MAF values in variant calling when 
using FamSeq (Figure 2.6). In contrast to the simulations, we did not observe a decrease in FPs in 
the child (NA12878 in g3). One explanation is we derived the input likelihood estimates from 
GATK, which may aggressively filter out FPs, but at a price of missing some true positives. 
This validation was performed at HapMap SNP positions, including all common SNPs whose 
known genotypes may have been used for calibration by GATK. Additionally, most of these 
SNPs (98%) are located in the noncoding region. Therefore, we look for larger improvements 
from using FamSeq for finding rare DNA variants at sequence sites where variant calling in the 
Single method has not been optimized. 
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Figure 2.5 Analysis of sequencing data in extended pedigrees. (A) HapMap SNP validation 
(Table 2.3). (B) FamSeq-unique variants found in 45 people (parents) in 25 families affected with 
mitochondrial disorders. (C) Coverage versus LLR in TS samples. All positions called 
concordantly by the Single method and FamSeq are shown in the background as a smoothed 
scatterplot. Red circles represent FamSeq-unique variants; black triangles represent Single-unique 
variants. (Figure reprint from Peng, G. et al PNAS, 2013) 
Figure 2.6 Effect of MAF values on variant calling on HapMap SNPs. The x-axis is plotted in a 
log10 scale. The false negative rate is calculated as the rate of reference or no calls for a variant 
genotype, in NA12892, who is a parent, and within positions presenting a true genotype 
configuration of 011. The false positive rate is calculated as the rate of variant calls for a 
reference genotype in NA12878, who is a child, and within positions presenting a true genotype 
configuration of 000. (Figure reprint from Peng, G. et al PNAS, 2013) 
 
 
 
found new positions in the affected child. This illustrates the
limitation of the Single method in detecting rare DNA variants
and demonstrates the power of using multigeneration pedigrees
to detect rare variants.
Coverage and Log Likelihood Ratios. FamSeq improved variant
calling in both WGS and targeted sequencing (TS) data at mean
base coverages from 25× to 1,200×. In the HapMap WGS data
(mean coverage 25–60×), FamSeq improved accuracy primarily
at positions with low-to-moderate coverage (15–20×; Table 1 and
SI Appendix, Fig. S4). NA12892 had the lowest mean coverage
(25×) and presented the biggest reduction in error rates among
the three samples (Fig. 4A). Compared with the WGS data, the
TS data have a wider range of mean coverage (200–1,200×).
However, FamSeq still called 1.2% more variants overall, at
coverage from 11 to 600× (median 24×; Fig. 4C and SI Appendix,
Fig. S3). To explore why, we correlated base coverage with log
likelihood ratio (LLR) (input for FamSeq) in all sequence data.
We expected a genotype-speciﬁc linear relationship between LLR
and coverage (SI Appendix, Fig. S5, r = 0.87 for heterozygotes, r =
0.80 for homozygous positions), which can be derived analytically
from the underlying binomial distribution used by Samtools and
GATK (20). FamSeq strengthens signals at positions with a low
LLR (LLR < 10). Therefore, it can improve variant calling in
sequencing data at positions with coverage 20× or lower. How-
ever, in TS data where most positions are at high coverage,
FamSeq called more variants in 381 positions, 234 (61%) of which
have high coverage (>20×) but still low LLR (<10), and thus show
a relationship that varies from the expected linear relationship
(Fig. 4C and SI Appendix, Fig. S5).
Discussion
We have developed a family-integrated method, FamSeq, which
uses Mendelian transmission information to inform the calling of
variants in raw sequence data. Such joint variant calling has been
reported to improve variant detection using simulated data (12).
In simulations, we identiﬁed factors that may affect the level of
improvements made by FamSeq, including family genotype con-
ﬁgurations, the prior setting of MAF, as well as pedigree size and
structure. Using actual sequence data from 28 families, we also
evaluated the performance of FamSeq in practical settings, using
WGS (WT family) or TS (families with mitochondrial disorders)
to determine the effect of variables such as known SNPs versus
unknown variants and moderate (20×) versus high sequencing
coverage (>200×). By looking across 45 samples from 25 families,
we accounted for biological and technical variations in real data
and observed a statistically signiﬁcant increase in variant de-
tection with an increase in family size. From our comparative
analysis of data with truth from two different studies using WGS,
we found that FamSeq increased the sensitivity of variant calling,
while still maintaining speciﬁcity. We project that the application
of FamSeq to sequencing data for rare variant detection in fam-
ilies with heritable diseases will yield signiﬁcant improvements at
low, moderate, and high sequencing coverage.
To be of practical use, variant calling algorithms that use
family data should be computationally efﬁcient and also account
for marriage loops and/or consanguinity. FamSeq uses a Bayes-
ian network to compute posterior probabilities, which results in
fast computation (in minutes for analyzing WGS data) with a
family size less than 7. The use of parallel probability calculations
will extend the utility of the Bayesian network approach to larger
families.
To allow for uncertainty in the estimates of LLRs, which will
further improve variant calling accuracy, FamSeq includes an
MCMC approach. The LLRs represent the signal-to-noise in-
formation from each family member. In 3,600 SNP positions
where both the Single method and FamSeq made mistakes, the
coverage as well as LLRs are higher than the average values,
suggesting a possible bias in the LLR estimates (SI Appendix, Fig.
S4). Thus, when variances on the LLR estimates are available,
our MCMC approach may be useful to correct variant calling at
more positions. Similarly, variances on the MAF estimates can
be incorporated when available.
The overall improvement by FamSeq is measured on a con-
tinuous scale as increased conﬁdence in the correct call for a
variant or reference position. FamSeq gives a posterior prob-
ability as the conﬁdence measure for variant calls. We compared
this with two conﬁdence measures derived from GATK. First, we
A B C
Fig. 4. Analysis of sequencing data in extended pedigrees. (A) HapMap SNP validation (SI Appendix, Table S3). (B) FamSeq-unique variants found in 45
people (parents) in 25 families affected with mitochondrial disorders. (C) Coverage versus LLR in TS samples. All positions called concordantly by the Single
method and FamSeq are shown in the background as a smoothed scatterplot. Red circles represent FamSeq-unique variants; black triangles represent
Single-unique variants.
Table 1. Mean base coverage of all loci with HapMap heterozygous calls in FamSeq
performance categories
FamSeq
Single Concordant Discordant N
Concordant 32 (sd = 10, n = 1.3M) 51 (sd = NA, n = 1) 16 (sd = 7, n = 126)
Discordant 16 (sd = 7, n = 254) 25 (sd = 11, n = 1784) 14 (sd = 8, n = 74)
N 15 (sd = 7, n = 658) 16 (sd = 8, n = 55) 14 (sd = 7, n = 758)
Cells in bold are where FamSeq improved on Single method (sd, standard deviation; n, the number of loci in
each category).
3988 | www.pnas.org/cgi/doi/10.1073/pnas.1222158110 Peng et al.
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Figure 2.7 Summary of individual variant calls over family size in the target sequencing data. A-
D) Distribution of unique variants added by either FamSeq or the Single method for each 
individual, 45 of whom are parents and 38 of whom are children. Shown is percentage of these 
unique calls in the concordant calls made by both methods. The total numbers of individuals at 
the corresponding family size are shown on top. E) Base coverage distribution for variant 
positions across the 45 individuals who are parents. The total numbers of variant positions for 
each category are shown on top. (Figure reprint from Peng, G. et al PNAS, 2013) 
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Table 2.4 Summary of individual variant calls from FamSeq and Single method across 26 
families with mitochondrial disorders. The calls are made in 762KB of coding sequences. Here C 
denotes child, FM denotes father or mother, GP denotes grandparents. (Table reprint from Peng, 
G. et al PNAS, 2013) 
 
!!
Table S4. Summary of individual variant calls from FamSeq and Single method
 across 26 families with mitochondrial disorders. 
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Table 2.5 Summary of variant positions from FamSeq and Single method across 26 families with 
mitochondrial disorders. The calls are made in 762KB of coding sequences. The column of 
FamSeq- Unique gives the number of variant positions where more variants were called in family 
members by FamSeq. The column of Single-Unique gives the number of variant positions where 
more variants were called in family members by Single method. The column of Both-Unique 
gives the number of positions where more variants were called in different family members by 
FamSeq or Single method. (Table reprint from Peng, G. et al PNAS, 2013) 
 
2.3.10 Targeted Sequencing Data Analysis in Families with Mitochondrial Neurodevelopmental 
Disorders. These families vary in size from 2 to 7 and include single-parent, nuclear, as well as 
three-generation families (Table 2.1). In each individual, we sequenced 524 nuclear-encoded 
mitochondrial candidate genes47,51 and focused our analysis on 962 Kb of coding regions in 
autosomes. We observed a significant increase in new variants called by FamSeq in the parents 
(Figure 2.5B and Table 2.4; FamSeq vs. Single method at size = 3: Kolmogorov-Smirnov test P < 
0.001; FamSeq vs. Single method at size = 4: P < 0.001; FamSeq at size=3 vs. 
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size=4:P<0.001,FamSeq at size=4 vs. size > 4, P = 0.06). We measured the significantly 
increased number of variants as related to family size in a total of 45 individuals from 25 different 
families, thus accounting for biological and technological variations between different sequenced 
individuals. We are currently validating these positions using Sanger-based sequencing, which 
may facilitate finding the unknown gene defects in these families. We did not observe significant 
increases in variants in the children (Figure 2.3C and Figure 2.7). However, the approximate 
reduction in FNRs (estimated by % FamSeq-unique variants) in the three-generation pedigree was 
1– 5%, which is substantially larger than the 0.1% observed at HapMap SNP positions (Table 
2.5) indicating the power of FamSeq in detecting rare variants. In three of these families, we 
found 15 unique variant positions (Table 2.5) that are not reported in the Single Nucleotide 
Polymorphism Database (dbSNP) or the 1,000 Genomes Project, nine of which are non- 
synonymous. We also analyzed family MTF04 in three ways: trio, trio plus either pair of 
grandparents, and trio plus both pairs of grandparents. Interestingly, compared with the Single 
method for this family, only the extended pedigree (size = 5 or 7) analysis found new positions in 
the affected child. This illustrates the limitation of the Single method in detecting rare DNA 
variants and demonstrates the power of using multigeneration pedigrees to detect rare variants. 
Table 2.6 Mean base coverage of all loci with HapMap heterozygous calls in FamSeq 
performance categories. (Table reprint from Peng, G. et al PNAS, 2013) 
 
 
 
found new positions in the affected child. This illustrates the
limitation of the Single method in detecting rare DNA variants
and demonstrates the power of using multigeneration pedigrees
to detect rare variants.
Coverage and Log Likelihood Ratios. FamSeq improv d variant
calling in both WGS and targeted sequencing (TS) data at mean
base coverages from 25× to 1,200×. In the HapMap WGS data
(mean coverage 25–60×), FamSeq improved accuracy primarily
at positions with low-to-moderate coverage (15–20×; Table 1 and
SI Appendix, Fig. S4). NA12892 had the lowest mean coverage
(25×) and presented the biggest reduction in error rates among
the three samples (Fig. 4A). Compared with the WGS data, the
TS data have a ider range of mean coverage (200–1,20 ×).
However, FamSeq still called 1.2% more variants overall, at
coverage from 11 to 600× (median 24×; Fig. 4C and SI Appendix,
Fig. S3). To explore why, we correlated base coverage with log
likelihood ratio (LLR) (input for FamSeq) in all sequence data.
We expected a genotype-speciﬁc linear relationship between LLR
and coverage (SI Appendix, Fig. S5, r = 0.87 for heterozygotes, r =
0.80 for homozygous positions), which can be derived analytically
from the underlying binomial distribution used by Samtools and
GATK (20). FamSeq strengthens signals at positions with a low
LLR (LLR < 10). Therefore, it can improve variant calling in
sequencing data at positions with coverage 20× or lower. How-
ever, in TS data where most positions are at high coverage,
FamSeq called more variants in 381 positions, 234 (61%) of which
have high coverage (>20×) but still low LLR (<10), and thus show
a relationship that varies from the expected linear relationship
(Fig. 4C and SI Appendix, Fig. S5).
Discussion
We have developed a family-integrated method, FamSeq, which
uses Mendelian transmission information to inform the calling of
variants in aw sequence data. Such joint variant calling has been
reported to improve variant detection using simulated data (12).
In simulations, we identiﬁed factors that may affect the level of
improvements made by FamSeq, including family genotype con-
ﬁgurations, the prior setting of MAF, as well as pedigree size and
structure. Using actual sequence data from 28 families, we also
evaluated the performance of FamSeq in practical settings, using
WGS (WT family) or TS (families with mitochondrial disorders)
to determine the effect of variables such as known SNPs versus
unknown variants and moderate (20×) versus high sequencing
coverage (>200×). By looking across 45 samples from 25 families,
we accounted for biological and technical variations in real data
and observed a statistically signiﬁcant increase in variant de-
tection with an increase in family size. From our comparative
analysis of data with truth from two different studies using WGS,
we fou d that FamSeq increased the sensitivity of variant calling,
while still maintaining speciﬁcity. We project that the application
of FamSeq to sequencing data for rare variant detection in fam-
ilies with heritable diseases will yield signiﬁcant improvements at
low, moderate, and high sequencing coverage.
To be of practical use, variant calling algorithms that use
family data should be computationally efﬁcient and also account
for marriage loops and/or consanguinity. FamSeq uses a Bayes-
ian network to compute posterior probabilities, which results in
fast computation (in minutes for analyzing WGS data) with a
family size less than 7. The use of parallel probability calculations
will extend the utility of the Bayesian network approach to larger
families.
To allow for uncertainty in the estimates of LLRs, which will
further improve variant calling accuracy, FamSeq includes an
MCMC approach. The LLRs represent the signal-to-noise in-
formation from each family member. In 3,600 SNP positions
where both the Single method and FamSeq made mistakes, the
coverage as well as LLRs are higher than the average values,
suggesting a possible bias in the LLR estimates (SI Appendix, Fig.
S4). Thus, when variances on the LLR estimates are available,
our MCMC approach may be useful to correct variant calling at
more positions. Similarly, variances on the MAF estimates can
be incorporated when available.
The overall improvement by FamS q is measured on a con-
tinuous scale as increased conﬁdence in the correct call for a
variant or reference position. FamSeq gives a posterior prob-
ability as the conﬁdence measure for variant calls. We compared
this with two conﬁdence measures derived from GATK. First, we
A B C
Fig. 4. Analysis of sequencing data in xtended pedigrees (A) HapMap SNP validation (SI Appendix, Table S3). (B) FamSeq-unique variants found in 45
people (parents) in 25 families affected with mitochondrial disorders. (C) Coverage versus LLR in TS samples. All positions called concordantly by the Single
method and FamSeq are shown in the background as a smoothed scatterplot. Red circles represent FamSeq-unique variants; black triangles represent
Single-unique variants.
Table 1. Mean base coverage of all loci with HapMap heterozygous calls in FamSeq
performance categories
FamSeq
Single Concordant Discordant N
Concordant 32 (sd = 10, n = 1.3M) 51 (sd = NA, n = 1) 16 (sd = 7, n = 126)
Discordant 16 (sd = 7, n = 254) 25 (sd = 11, n = 1784) 14 (sd = 8, n = 74)
N 15 (sd = 7, n = 658) 16 (sd = 8, n = 55) 14 (sd = 7, n = 758)
Cells in bold are where FamSeq improved on Single method (sd, standard deviation; n, the number of loci in
each category).
3988 | www.pnas.org/cgi/doi/10.1073/pnas.1222158110 Peng et al.
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Figure 2.8 Distributions of coverage within positions, as categorized by their variant calling 
results from both the Single (individual-based) and FamSeq methods. Comparing HapMap SNP 
calls for “S”, individual method, or for “F”, FamSeq, we separated positions into nine categories 
using “+” suggesting concordance, “-” suggesting discordance and “N” suggesting no call. The 
total number of positions in each category is shown at the bottom of the boxplots. Improvements 
made by FamSeq correspond to categories “S-F+”, “S-FN”, and “SNF+” (grey boxes). In 
positions with heterozygous variants: for “S-F+”, the median coverage is 16 and the range is 2 to 
80; for “S-FN”, the median coverage is 14, and the range is 2 to 37; for “SNF+”, the median 
coverage is 14, and the range is 1 to 87. (Figure reprint from Peng, G. et al PNAS, 2013) 
 
2.3.11 Coverage and Log Likelihood Ratios. FamSeq improved variant calling in both WGS and 
TS data at mean base coverages from 25× to 1,200×. In the HapMap WGS data (mean coverage 
25–60×), FamSeq improved accuracy primarily at positions with low-to-moderate coverage (15–
20×; Table 2.6 and Figure 2.8). NA12892 had the lowest mean coverage (25×) and presented the 
biggest reduction in error rates among the three samples (Figure 2.5A). Compared with the WGS 
data, the TS data have a wider range of mean coverage (200–1,200×). However, FamSeq still 
called 1.2% more variants overall, at coverage from 11 to 600× (median 24×; Figure 2.5C and 
Figure 2.7). To explore why, we correlated base coverage with log likelihood ratio (LLR) (input 
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for FamSeq) in all sequence data. We expected a genotype-specific linear relationship between 
LLR and coverage (Figure 2.9, r = 0.87 for heterozygotes, r = 0.80 for homozygous positions), 
which can be derived analytically from the underlying binomial distribution used by Samtools 
and GATK. FamSeq strengthens signals at positions with a low LLR (LLR < 10). Therefore, it 
can improve variant calling in sequencing data at positions with coverage 20× or lower. How- 
ever, in TS data where most positions are at high coverage, FamSeq called more variants in 381 
positions, 234 (61%) of which have high coverage (>20×) but still low LLR (<10), and thus show 
a relationship that varies from the expected linear relationship (Figure 2.5C and Figure 2.9). 
Figure 2.9 Smoothed scatterplot of log10 likelihood ratio over coverage for whole-genome 
sequencing data. A) shows data generated by Illumina GAII technology (NA12891, NA12892 
and NA12878). B) shows data generated by Illumina HiSeq2000 technology (NA12882 and 
NA12877). For each panel, we randomly sampled values from 150,000 positions out of 3,000,000 
positions for all samples combined. The two clusters observed are for positions with homozygous 
calls, and with heterozygous calls, separately. A loess curve for each cluster is shown. These lines 
suggest a linear relationship between log10 likelihood ratio and coverage, and present different 
slopes for heterozygous calls (slope=1.1 and 1.4, which is approximately -0.5log10(4e), with a 
corresponding error rate e of 0.002 and 0.0004 for the two technologies respectively) and 
homozygous calls (slope=0.27 and 0.29, which is approximately log10(2) for the two 
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technologies respectively). The mathematical derivation is based on a binominal distribution for 
variant calling, as described by Li et al. (2009). (Figure reprint from Peng, G. et al PNAS, 2013) 
 
2.4  Discussion 
We have developed a family-integrated method, FamSeq, which uses Mendelian transmission 
information to inform the calling of variants in raw sequence data. Such joint variant calling has 
been reported to improve variant detection using simulated data21. In simulations, we identified 
factors that may affect the level of improvements made by FamSeq, including family genotype 
con- figurations, the prior setting of MAF, as well as pedigree size and structure. Using actual 
sequence data from 28 families, we also evaluated the performance of FamSeq in practical 
settings, using WGS (WT family) or TS (families with mitochondrial disorders) to determine the 
effect of variables such as known SNPs versus unknown variants and moderate (20×) versus high 
sequencing coverage (>200×). By looking across 45 samples from 25 families, we accounted for 
biological and technical variations in real data and observed a statistically significant increase in 
variant detection with an increase in family size. From our comparative analysis of data with truth 
from two different studies using WGS, we found that FamSeq increased the sensitivity of variant 
calling, while still maintaining specificity. We project that the application of FamSeq to 
sequencing data for rare variant detection in families with heritable diseases will yield significant 
improvements at low, moderate, and high sequencing coverage. 
To be of practical use, variant calling algorithms that use family data should be 
computationally efficient and also account for marriage loops and/or consanguinity. FamSeq uses 
a Bayesian network to compute posterior probabilities, which results in fast computation (in 
minutes for analyzing WGS data) with a family size less than 7. The use of parallel probability 
calculations will extend the utility of the Bayesian network approach to larger families. 
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To allow for uncertainty in the estimates of LLRs, which will further improve variant calling 
accuracy, FamSeq includes an MCMC approach. The LLRs represent the signal-to-noise in- 
formation from each family member. In 3,600 SNP positions where both the Single method and 
FamSeq made mistakes, the coverage as well as LLRs are higher than the average values, 
suggesting a possible bias in the LLR estimates (Figure 2.8). Thus, when variances on the LLR 
estimates are available, our MCMC approach may be useful to correct variant calling at more 
positions. Similarly, variances on the MAF estimates can be incorporated when available. 
The overall improvement by FamSeq is measured on a continuous scale as increased 
confidence in the correct call for a variant or reference position. FamSeq gives a posterior 
probability as the confidence measure for variant calls. We compared this with two confidence 
measures derived from GATK. First, we examined the quality tranches that used HapMap SNP 
truths to define cutoffs; second, the individual-based posterior probability at positions that passed 
our hard-filtering criteria. We used the quality tranches in analyzing the WGS data for the WT 
family and used a cutoff at the last tranche level: 99.9–100 (less specific than other levels). We 
used posterior probabilities in the other analyses and a cutoff at 90%, because these analyses are 
either for comparison with HapMap SNPs or for TS data (where quality tranches cannot be 
reliably generated). We considered any call with a confidence measure at or below the cutoff as a 
“no call.” In the HapMap data, FamSeq reduced the overall no call rate at the SNP positions by 
giving reference or variant calls at higher confidence (Table 2.3). Changing cutoffs can shift the 
balance between the FNR, FPR, and no call rate in the Single method and in the comparison with 
FamSeq. Regardless of the cutoffs, FamSeq provides a confidence measure that incorporates 
family information and, compared with the Single method, better describes the uncertainty of 
individual genotype calls, which improves the overall accuracy. 
We identify two key questions for balancing cost with obtaining adequate data to identify the 
disease variant of interest. (i) Who should be selected from a large family for initial sequencing? 
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(ii) At what coverage depth should selected family members be sequenced? FN variant calls are 
of great concern in these types of gene identification studies. We found that adding both parents 
and then grandparents before adding more siblings was most effective. One explanation is when 
the LLRs for the parents are similar but only one parent has a heterozygous variant, adding data 
from one set of grandparents (the parents of one parent) can break the tie and help identify which 
parent carries the variant, whereas adding data from more children cannot. Additionally, we 
determined that WGS data generated at an average of 25–30× coverage per person will most 
benefit from FamSeq analysis. While overall coverage in the WT data were ∼30×, about 5–20% 
of all base positions had a coverage of <20× nevertheless. FamSeq was highly beneficial in 
correcting calling errors made at these positions (Table 2.6). In sequencing data (especially TS 
data) generated at an overall high coverage (200– 1,200×), FamSeq is still valuable for variant 
calling as there will still be positions with low coverage and also positions with high coverage but 
small LLR (<10). These outlier positions are likely caused by sequence-specific technical errors, 
allelic imbalance, or other unobservable factors. 
We identified factors that can facilitate the analysis and interpretation of family sequencing 
studies. Using simulations with FamSeq analysis, we showed the choice of MAF had little effect 
on the FNRs and FPRs in children, and the FNRs in parents, but can still affect the FPRs in 
parents (Figure 2.3C). This remaining effect can be alleviated in two ways: (i) setting an MAF of 
0.001 or less to control for the FPR, while maintaining the power to detect true variants by using 
FamSeq, and (ii) prefiltering FP positions, which appear to be implemented in GATK for 
HapMap SNPs (Figure 2.6; little reduction in FPR by FamSeq was observed with the HapMap 
sample originally processed by GATK). For comparison, we observed FamSeq substantially 
reduced the FPR in HapMap SNPs on data generated by Samtools, which is less suited to 
removing FPs. 
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In both simulations and real data (Figure 2.3A and Figure 2.4 and 2.8 and Table 2.3), we 
showed that FamSeq can mistakenly change calls from the individual-based method, although 
this happens rarely compared with the corrections it makes (1–3% vs. 14–33% in HapMap SNPs, 
P < 0.001). Therefore, when comparing results from the Single method and FamSeq, we suggest 
giving high priority to positions at which FamSeq changed a de novo mutation to either a 
Mendelian mutation or to a reference position, or added variant calls in parents or removed them 
in children. This prioritization needs to be integrated into the generation of lists of validation 
variants. In general, family-based analysis improves both sensitivity and specificity of calling 
Mendelian mutations. However, in the case of de novo mutation calls, this decrease in FPs may 
increase FNs in some occasions. 
We studied two diseases, one with a dominant trait and one with suspected recessive 
inheritance. For the family affected with WT (autosomal dominant), we took advantage of the 
large pedigree (Figure 2.2) and previous linkage mapping and used a 3+2 design: a family trio 
with affected parent and child and two affected distant relatives. Sequence variants identified in 
the affected mother and son and two other relatives but not in the unaffected parent are candidates 
for follow-up analysis. For further sequencing, we prioritized the grandparents of the trio to 
uncover additional variants. Linkage information was not available for the families with 
mitochondrial disease, which is a genetically and clinically heterogeneous group of disorders51, 
making disease-related gene discovery very challenging. One approach relies on filtering against 
public SNP databases for genes with two rare functional variants (homozygous or compound 
heterozygous) present only in the affected individuals2. Notably, an analysis of our targeted 
sequence data of 524 genes identified relatively more recessive candidate genes in the larger 
families (e.g., MTF04) compared with smaller families. These positions are being validated. 
Our method is implemented in a C++ based software called FamSeq, which is freely 
available. It can process variable pedi- gree structures and accommodate de novo mutations. It 
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contains three approaches: a Bayesian network, an MCMC algorithm, and the Elston-Stewart 
algorithm. For a variant call format (VCF) file containing 3.5 M variant positions for a pedigree 
of seven members without loops [on an Intel(R) Xeon(R) processor with a CPU at 2.93 GHz], the 
respective computing times are 550 s, 550 s, and 10,000 s (10,000 iterations) for the Bayesian 
network, Elston-Stewart, and MCMC, respectively. When a loop is added to this pedigree, we 
observe little change in computing times for the Bayesian network and MCMC methods, but can 
increase time of at least 20–50% for loop-cutting within the Elston-Stewart algorithm52. FamSeq 
is a stand-alone module that can be integrated with existing analysis pipelines of data generated 
from different high-throughput platforms, both sequencing-based and array-based data13-15,50. Our 
method can be extended to give joint posterior probabilities for calling short indels in sequenced 
families15. Thus, FamSeq provides a facile and flexible means of reducing FN sequence calls, and 
will greatly aid in identifying disease-causing variants in next-generation sequencing studies. 
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3. Implementation of Variant Calling for Family-Based Sequencing Data Using 
Graphics Processing Units 
This chapter is based upon the journal paper: Peng G., Fan Y., Wang W. “FamSeq: A Variant 
Calling Program for Family-Based Sequencing Data Using Graphics Processing Units”. PLoS 
Comput Biol 10(10): e1003880. doi:10.1371/journal.pcbi.1003880 (2014). According to the 
journal policy, the author retains the right to include the published article in full or in part in a 
dissertation. 
3.1 Introduction 
Next-generation sequencing technologies have been employed routinely in detecting DNA 
variants and unveiling the cause of genetic diseases53. The broad application of next-generation 
sequencing technologies has led to an accompanying rapid development in variant calling 
algorithms and related software13-15,17. However, the variant calling error rate remains relatively 
high for rare variants54, even though many new methods have been employed to improve variant 
calling, such as calling multiple samples together and borrowing information from the dbSNP 
database55. 
Roach et al. suggested using pedigree information to reduce the false positive rate of variant 
calling by removing all variants that do not conform to Mendelian transmission18. However, this 
method cannot control the false negative rate and cannot find any de novo mutations. Pedigree 
information has also been used to improve the accuracy for haplotype phasing in small 
families19,45. Recent studies have shown that incorporating pedigree information into the variant 
calling reduces both false positive and false negative rates for family trios and extended 
families16,21,56. Peng et al. showed that in some HapMap families, incorporating pedigree 
information can reduce the false positive rates by 14–33% 56. 
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Several software packages have been implemented to incorpo- rate pedigree information for 
variant calling. SAMtools16 and DeNovoGear57 can process family trios together. The Elston- 
Stewart algorithm was used in PolyMutt21 to incorporate extended families. However, the Elston-
Stewart algorithm requires either loop-cutting techniques, which will substantially increase the 
computing time and give approximate answers that are not always close to the exact results26, or 
the use of the method proposed by Cannings et al.27 that is hard to implement and has large 
memory requirements. Peng et al. proposed additional computational solutions for implementing 
the Mendelian genetic model in sequence variant calling56. The Bayesian network algorithm, in 
particular, provides exact results for a family pedigree with inbreeding loops. In order to allow for 
uncertainty in the minor allele frequency estimation, we also implemented a Markov chain Monte 
Carlo algorithm24 to perform the family-based variant calling. To incorporate pedigree 
information into variant calling, we provide a program, FamSeq, that allows users to choose 
among the four following approaches, the Elston-Stewart algorithm, the Bayesian network 
algorithm, the graphics processing unit (GPU) version of the Bayesian network algorithm and the 
Markov chain Monte Carlo algorithm. FamSeq further improves the computational efficiency by 
using the GPU. 
In whole genome sequencing, there are billions of loci with millions of candidate variant 
positions, so computing time is always a problem. We therefore sought to parallelize the Bayesian 
network algorithm in order to make the computing time feasible for analyzing a large set of whole 
genome sequencing data. GPUs were originally designed to accelerate the processing of graphics. 
As GPUs have become more programmable and have performed powerfully in parallel 
computing, they have been widely used in general-purpose applications, including those used in 
bioinformatics58-60. The Bayesian network algorithm contains many homogeneous tasks that can 
be accomplished by GPU parallel computing. Therefore, we implemented the parallel computing 
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of the Bayesian network algorithm using the CUDA parallel computing platform on an NVIDIA 
GPU, which substantially increased the performance of that algorithm. 
 
3.2 Design and Implementation 
3.2.1 Design Overview. We developed a software package, FamSeq, which calls variants for 
family-based sequencing data. We used different methods to implement Mendelian transmission 
in FamSeq. 
Figure 3.1 Workflow of FamSeq. We use a pedigree file and a file that includes the likelihood 
(Pr(D|G)) as the input to estimate the posterior probability (Pr(G|D)) for each variant genotype. 
(E-S: Elston-Stewart algorithm; BN: Bayesian network method; BN-GPU: The computer needs a 
GPU card installed to run the GPU version of the Bayesian network method; MCMC: Markov 
chain Monte Carlo method; VCF: variant call format.) (Figure reprint from Peng, G. et al PLoS 
Comput Biol, 2014) 
As outlined in the workflow of FamSeq (Figure 3.1), two files are required as data input: a 
pedigree structure file and a file containing the genotype likelihood Pr(D|G), where D denotes the 
raw sequencing measurements, i.e., read counts, read quality and mapping quality, and G denotes 
the genotype of the individual. The pedigree file stores the individual identification (ID), parents’ 
calling. To incorporate pedigree information into variant calling,
we provide a program, FamSeq, that allows users to choose among
the four following approaches, the Elston-Stewart algorithm, the
Bayesian network algorithm, the graphics processing unit (GPU)
version of the Bayesian network algorithm and the Markov chain
Monte Carlo algorithm. FamSeq further improves the computa-
tional efficiency by using the GPU.
In whole genome sequencing, there are billions of loci with
millions of candidate variant positions, so computing time is
always a problem. We therefore sought to parallelize the Bayesian
network algorithm in order to make the computing time feasible
for analyzing a large set of whole genome sequencing data. GPUs
were originally designed to accelerate the processing of graphics.
As GPUs have become more programmable and have performed
powerfully in parallel computing, they have been widely used in
general-purpose applications, including those used in bioinfor-
matics [18–20]. The Bayesian network algorithm contains many
homogeneous tasks that can be accomplished by GPU parallel
computing. Therefore, we implemented the parallel computing of
the Bayesian network algorithm using the CUDA parallel
computing platform on an NVIDIA GPU, which substantially
increased the performance of that algorithm.
Design and Implementation
Design Overview
We developed a software package, FamSeq, which calls variants
for family-based sequencing data. We used different methods to
implement Mendelian transmission in FamSeq.
As outlined in the workflow of FamSeq (Fig. 1), two files are
required as data input: a pedigree structure file and a file
containing the genotype likelihood Pr DDGð Þ, where D denotes the
raw sequencing measurements, i.e., read counts, read quality and
mapping quality, and G denotes the genotype of the individual.
The pedigree file stores the individual identification (ID), parents’
IDs, and gender and sample name, as is used to denote samples in
the likelihood data file (Fig. 2). FamSeq accepts likelihood data
files in two formats: a variant call format (VCF) [21] and a
likelihood-only format (see description in our software manual).
We introduced the likelihood-only format to allow for data
generated from other sequencing platforms, with the requirement
that the likelihood for each genotype is available.
FamSeq takes as input the two data files and settings of parameters
(details on allele frequency and de novo mutation rate are shown
hereafter). A data preprocessing feature of FamSeq will check
whether there are any errors in the two input files. After that, FamSeq
will implement the method the user chooses to call the variants.
FamSeq creates a new file as the output file, which follows the
format of the input file but adds additional columns, with results
on the posterior probability and the genotype, calculated using
both the individual-based method and the family-based method.
Data Preprocessing
FamSeq first checks the pedigree file. FamSeq requires the input
pedigree to be complete, which means that everyone listed in the
pedigree should have both a father and a mother represented in
the pedigree file, with the exception of the founders of the family
(Fig. 2). Otherwise, if two siblings have only one parent’s
information in the pedigree, FamSeq cannot determine whether
they are full siblings or half siblings. FamSeq also checks for any
inconsistency in the pedigree file, such as the father being
erroneously listed as female. FamSeq extracts likelihood informa-
tion from the Phred-scaled likelihood (PL) section in a VCF file or
directly from a likelihood-only file.
Input of Allele and Genotype Frequency in the
Population
We require Pr Gð Þ, which is the probability of the genotype in a
population. In FamSeq, we consider a bi-allelic model with
reference (R) and alternative (A) alleles. Consequently, there are
three kinds of genotypes in a diploid genome: RR, RA and AA.
Without compromising the detection of true variants, we set the
default value of the frequency of three genotypes in the population
at 0.9985, 0.001 and 0.0005 if the variant is not represented in
dbSNP. The dbSNP information should be provided by the input
VCF file. For dbSNPs, the default value is set at 0.45, 0.1 and
0.45. Users can choose to set other values. When only the allele
frequency is known, users can set genotype frequencies based on
the Hardy-Weinberg equilibrium [22]. Based on findings from
Peng et al., changes in the values of Pr Gð Þ can affect the variant
calling results of the founders, while its influence on offsprings in
the family is small [12].
Rate of De Novo Mutation
In FamSeq, we require the input of the de novo mutation rate by
assigning a probability of m for each parental allele to mutate into
the other allele in the germline [12]. In other words, when the two
parents have homozygous reference genotypes, there is still a
probability that their child has a genotype with an alternative allele.
We added the de novo mutation rate in the calculation of
transmission probabilities (described underModel Implementation).
The de novo mutation rate has been estimated to be around
1e28 per base per generation [23]. When we analyzed real data,
we found that the rates of false positives and false negatives were
better controlled when a de novo mutation rate was set at 1e27.
Thus, we set a de novo mutation rate of 1e27 as the default in
FamSeq. Users can set the de novo mutation rate according to
their requirements. In general, when the de novo mutation rate is
set to a large value, the influence of pedigree-to-variant calling is
small and the identification of more de novo mutations is allowed
during variant calling.
Even though we allow for de novo mutations in our model, we
still may over-correct the variant calling at some loci by following
Figure 1. Workflow of FamSeq.We use a pedigree file and a file that
includes the likelihood (Pr DDGð Þ) as the input to estimate the posterior
probabili y (Pr GDð Þ) for each variant genotype. (E-S: Elston-Stewart
algorithm; BN: Bayesian network method; BN-GPU: The computer needs
a GPU card installed to run the GPU version of the Bayesian network
method; MCMC: Markov chain Monte Carlo method; VCF: variant call
format.)
doi:10.1371/journal.pcbi.1003880.g001
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IDs, and gender and sample name, as is used to denote samples in the likelihood data file (Figure 
3.2). FamSeq accepts likelihood data files in two formats: a variant call format (VCF)61 and a 
likelihood-only format (see description in our software manual). We introduced the likelihood-
only format to allow for data generated from other sequencing platforms, with the requirement 
that the likelihood for each genotype is available. 
Figure 3.2 Illustration of input files. A.) Pedigree structure. B.) Pedigree structure file storing the 
pedigree structure shown in Figure 3.2A. From the left-most column to the right-most column, 
the data are ID, mID (mother ID), fID (father ID), gender and sample name. C.) Part of VCF file. 
From the VCF file, we can find that the genome of the grandfather (G-Father) was not sequenced. 
We add his information to the pedigree structure file to avoid ambiguity. For example, if we 
include only one parent of two siblings in the pedigree structure file, it will be unclear whether 
they are full or half siblings. The sample name in the pedigree structure file should be the same as 
the sample name in the VCF file. When the actual genome was not sequenced, we set the 
corresponding sample name as NA in the pedigree structure file. (Figure reprint from Peng, G. et 
al PLoS Comput Biol, 2014) 
Mendelian inheritance principles when there are true de novo
mutations. Therefore, we provide the following option to alleviate
the over-correction: when the likelihood ratio for all individuals in
the pedigree is larger than a user-specified cutoff and the
genotypes do not follow Mendel’s law, FamSeq will call variants
using the individual-based method instead of the family-based
method.
Method Implementation
Markov chain Monte Carlo (MCMC) algorithm. We use
the Gibbs sampler to derive the posterior probabilities for each
genotype [17,24]. During Gibbs sampling, the genotype of each
individual in the family is updated, one at a time, based on the
condition of all other family members’ genotypes, the family
configuration and the raw sequencing measurements. According
to Mendelian segregation principles, the genotype of the individual
does not depend on those of all family members, but only on the
individual’s parents, spouse and children. We can write the full
conditionals as follows:
f Gið Þ~Pr Gi DG{i,D,Pð Þ~Pr Gi DGfi ,Gmi ,Gci ,Gsi ,D
! "
!Pr Gi DGfi ,Gmi
! "
PJij~1 Pr Gcij DGsij ,Gi
# $
Pr Di DGið Þ
ð1Þ
where Gi denotes the genotype for individual i, G{i denotes the
genotype for all family members, except individual i, D denotes
the raw sequencing measurements, and P denotes the pedigree
configuration. Gfi , Gmi , Gci and Gsi indicate the genotype of
individual i’s father, mother, child and spouse. Pr Gi DGfi ,Gmi
! "
is
the tr nsmission probability, which shows how the parents’
genotypes influence the child’s genotype.
To avoid a local maximization problem in the Gibbs sampler,
w also implemented a heated-Metropolis algorithm in MCMC, as
proposed by Lin et al. [24]. In the heated-Metropolis algorithm,Gi
is sampled from a distribution of f Gið Þ1=T instead of f Gið Þ. The
sampled _Gi is accepted with the probabilitymin
f _Gi
! "
f Gið Þ
" #1{1=T
,1
8<:
9=;.
The accuracy of the MCMC algorithm depends on the number
of iterations. As is shown in Biswas et al. [17], the MCMC
approach requires tens of thousands of iterations to converge for a
large pedigree; therefore, the computing time will also increase. By
default, we set the number of iterations at 20,000n, where n is the
pedigree size. Users can specify the number of iterations according
to their needs.
Elston-Stewart algorithm. This algorithm splits the whole
pedigree into anterior and posterior parts according to the
individual of interest [25]. The anterior part relates to the parents
of the individual, and the posterior part relates to the child/
children of the individual. The probability of the anterior and
posterior parts can be estimated recursively, such that the posterior
genotype probability is calculated according to the probability of
the anterior part and the posterior part. The Elston-Stewart
algorithm is especially complex when there are inbreeding loops in
Figure 2. Illustration of input files. A.) Pedigree structure. B.) Pedigree structure file storing the pedigree structure shown in Fig. 2A. From the
left-most column to the right-most column, the data are ID, mID (mother ID), fID (father ID), gender and sample name. C.) Part of VCF file. From the
VCF file, we can find that the genome of the grandfather (G-Father) was not sequenced. We add his information to the pedigree structure file to avoid
ambiguity. For example, if we include only one parent of two siblings in the pedigree structure file, it will be unclear whether they are full or half
siblings. The sample name in the pedigree structure file should be the same as the sample name in the VCF file. When the actual genome was not
sequenced, we set the corresponding sample name as NA in the pedigree structure file.
doi:10.1371/journal.pcbi.1003880.g002
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FamSeq takes as input the two data files and settings of parameters (details on allele 
frequency and de novo mutation rate are shown hereafter). A data preprocessing feature of 
FamSeq will check whether there are any errors in the two input files. After that, FamSeq will 
implement the method the user chooses to call the variants. 
FamSeq creates a new file as the output file, which follows the format of the input file but 
adds additional columns, with results on the posterior probability and the genotype, calculated 
using both the individual-based method and the family-based method. 
 
3.2.2 Data Preprocessing. FamSeq first checks the pedigree file. FamSeq requires the input 
pedigree to be complete, which means that everyone listed in the pedigree should have both a 
father and a mother represented in the pedigree file, with the exception of the founders of the 
family (Figure 3.2). Otherwise, if two siblings have only one parent’s information in the pedigree, 
FamSeq cannot determine whether they are full siblings or half siblings. FamSeq also checks for 
any inconsistency in the pedigree file, such as the father being erroneously listed as female. 
FamSeq extracts likelihood informa- tion from the Phred-scaled likelihood (PL) section in a VCF 
file or directly from a likelihood-only file. 
 
3.2.3 Input of Allele and Genotype Frequency in the Population. We require Pr(G), which is the 
probability of the genotype in a population. In FamSeq, we consider a bi-allelic model with 
reference (R) and alternative (A) alleles. Consequently, there are three kinds of genotypes in a 
diploid genome: RR, RA and AA. Without compromising the detection of true variants, we set 
the default value of the frequency of three genotypes in the population at 0.9985, 0.001 and 
0.0005 if the variant is not represented in dbSNP. The dbSNP information should be provided by 
the input VCF file. For dbSNPs, the default value is set at 0.45, 0.1 and 0.45. Users can choose to 
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set other values. When only the allele frequency is known, users can set genotype frequencies 
based on the Hardy-Weinberg equilibrium62. Based on findings from Peng et al., changes in the 
values of Pr(G) can affect the variant calling results of the founders, while its influence on 
offsprings in the family is small56. 
 
3.2.4 Rate of De Novo Mutation. In FamSeq, we require the input of the de novo mutation rate by 
assigning a probability of m for each parental allele to mutate into the other allele in the 
germline56. In other words, when the two parents have homozygous reference genotypes, there is 
still a probability that their child has a genotype with an alternative allele. We added the de novo 
mutation rate in the calculation of transmission probabilities (described under Model 
Implementation). 
The de novo mutation rate has been estimated to be around 1e-8 per base per generation20. 
When we analyzed real data, we found that the rates of false positives and false negatives were 
better controlled when a de novo mutation rate was set at 1e-7. Thus, we set a de novo mutation 
rate of 1e-7 as the default in FamSeq. Users can set the de novo mutation rate according to their 
requirements. In general, when the de novo mutation rate is set to a large value, the influence of 
pedigree-to-variant calling is small and the identification of more de novo mutations is allowed 
during variant calling. 
Even though we allow for de novo mutations in our model, we still may over-correct the 
variant calling at some loci by following Mendelian inheritance principles when there are true de 
novo mutations. Therefore, we provide the following option to alleviate the over-correction: when 
the likelihood ratio for all individuals in the pedigree is larger than a user-specified cutoff and the 
genotypes do not follow Mendel’s law, FamSeq will call variants using the individual-based 
method instead of the family-based method. 
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3.2.5 Method Implementation 
Markov chain Monte Carlo (MCMC) algorithm. We use the Gibbs sampler to derive the 
posterior probabilities for each genotype24,25. During Gibbs sampling, the genotype of each 
individual in the family is updated, one at a time, based on the condition of all other family 
members’ genotypes, the family configuration and the raw sequencing measurements. According 
to Mendelian segregation principles, the genotype of the individual does not depend on those of 
all family members, but only on the individual’s parents, spouse and children. We can write the 
full conditionals as follows: 
 (3.1) 
where Gi denotes the genotype for individual i, G-i denotes the genotype for all family members, 
except individual i, D denotes the raw sequencing measurements, and P denotes the pedigree 
configuration. Gfi , Gmi , Gci and Gsi indicate the genotype of individual i’s father, mother, child 
and spouse. Pr(Gi|Gfi,Gmi) is the transmission probability, which shows how the parents’ 
genotypes influence the child’s genotype. 
To avoid a local maximization problem in the Gibbs sampler, we also implemented a heated-
Metropolis algorithm in MCMC, as proposed by Lin et al.25. In the heated-Metropolis algorithm, 
Gi is sampled from a distribution of f(Gi)1/T instead of f(Gi). The sampled ! i is accepted with the 
probability min ! !!! !! !!!/! , 1 . 
The accuracy of the MCMC algorithm depends on the number of iterations. As is shown in 
Biswas et al.24, the MCMC approach requires tens of thousands of iterations to converge for a 
large pedigree; therefore, the computing time will also increase. By default, we set the number of 
iterations at 20,000n, where n is the pedigree size. Users can specify the number of iterations 
according to their needs. 
Mendelian inheritance principles when there are true de novo
mutations. Therefore, we provide the following option to alleviate
the over-correction: when the likelihood ratio for all individuals in
the pedigree is larger than a user-specified cutoff and the
genotypes do not follow Mendel’s law, FamSeq will call variants
using the individual-based method instead of the family-based
method.
Method Implementation
Markov ch in Monte Carlo (MCMC) lgorithm. We use
the Gibbs sampler to derive the posterior probabilities for each
genotype [17,24]. During Gibbs sampling, the genotype of each
individual in the family is updated, one at a time, based on the
condition of all other family members’ genotypes, the family
configuration and the raw sequencing measurements. According
to Mendelian segregation principles, the genotype of the individual
does not depend on those of all family members, but only on the
individual’s parents, spouse and children. We can write the full
conditionals as follows:
f Gið Þ~Pr Gi DG{i,D,Pð Þ~Pr Gi DGfi ,Gmi ,Gci ,Gsi ,D
! "
!Pr Gi DGfi ,Gmi
! "
PJij~1 Pr Gcij DGsij ,Gi
# $
Pr Di DGið Þ
ð1Þ
where Gi denotes the genotype for individual i, G{i denotes the
genotype for all family members, except individual i, D denotes
the raw sequencing measurements, and P denotes the pedigree
configuration. Gfi , Gmi , Gci and Gsi indicate the genotype of
individual i’s father, mother, child and spouse. Pr Gi DGfi ,Gmi
! "
is
the transmission probability, which shows how the parents’
genotypes influence the child’s genotype.
To avoid a local maximization problem in the Gibbs sampler,
we also implemented a heated-Metropolis algorithm in MCMC, as
proposed by Lin et al. [24]. In the heated-Metropolis algorithm,Gi
is sampled from a distribution of f Gið Þ1=T instead of f Gið Þ. The
sampled _Gi is accepted with the probabilitymin
f _Gi
! "
f Gið Þ
" #1{1=T
,1
8<:
9=;.
The accuracy of the MCMC algorithm depends on the number
of iterations. As is shown in Biswas et al. [17], the MCMC
approach requires tens of thousands of iterations to converge for a
large pedigree; therefore, the computing time will also increase. By
default, we set the number of iterations at 20,000n, where n is the
pedigree size. Users can specify the number of iterations according
to their needs.
Elston-Stewart algorithm. This algorithm splits the whole
pedigree into anterior and posterior parts according to the
individual of interest [25]. The anterior part relates to the parents
of the individual, and the posterior part relates to the child/
children of the individual. The probability of the anterior and
posterior parts can be estimated recursively, such that the posterior
genotype probability is calculated according to the probability of
the anterior part and the posterior part. The Elston-Stewart
algorithm is especially complex when there are inbreeding loops in
Figure 2. Illustration of input files. A.) Pedigree structure. B.) Pedigree structure file storing the pedigree structure shown in Fig. 2A. From the
left-most column to the right-most column, the data are ID, mID (mother ID), fID (father ID), gender and sample name. C.) Part of VCF file. From the
VCF file, we can find that the genome of the grandfather (G-Father) was not sequenced. We add his information to the pedigree structure file to avoid
ambiguity. For example, if we include only one parent of two siblings in the pedigree structure file, it will be unclear whether they are full or half
siblings. The sample name in the pedigree structure file should be the same as the sample name in the VCF file. When the actual genome was not
sequenced, we set the corresponding sample name as NA in the pedigree structure file.
doi:10.1371/journal.pcbi.1003880.g002
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Elston-Stewart algorithm. This algorithm splits the whole pedigree into anterior and 
posterior parts according to the individual of interest23. The anterior part relates to the parents of 
the individual, and the posterior part relates to the child/children of the individual. The probability 
of the anterior and posterior parts can be estimated recursively, such that the posterior genotype 
probability is calculated according to the probability of the anterior part and the posterior part. 
The Elston-Stewart algorithm is especially complex when there are inbreeding loops in the 
pedigree because then the pedigree cannot be directly split into anterior and posterior parts. There 
are two methods to solve this problem. First, we can cut the loops according to complex criteria 
and obtain an approximate result26,63. Cannings et al. suggested using another method to obtain 
the analytical results27. However, their method has large memory requirements and is hard to 
implement. 
Bayesian network algorithm. By treating the entire pedigree as a directed acyclic graph (a 
Bayesian network), the genotype of sample i depends on the genotypes of only his/her parents22. 
We can write the posterior probability as 
 (3.2) 
The Bayesian network approach directly calculates the joint probabilities for all the combinations 
of genotypes of the whole family, and allows for analytic calculations for pedigrees with 
inbreeding loops. The Bayesian network approach is straightforward and easy to implement; 
however, the computing time increases exponentially when the pedigree size increases, so a 
supplementary approach is needed for a larger pedigree. 
Bayesian network parallelization. For variant calling using whole genome sequencing data, 
there are billions of loci. After filtering by FamSeq, there are still millions of candidate variant 
positions remaining; thus, we propose to parallelize the Bayesian network algorithm in order to 
reduce the computing time and make this approach feasible in the DNA sequencing data analysis. 
the pedigree because then the pedigree cannot be directly split into
anterior and posterior parts. There are two methods to solve this
problem. First, we can cut the loops according to complex criteria
and obtain an approximate result [15,26]. Cannings et al.
suggested using another method to obtain the analytical results
[16]. However, their method has large memory requirements.
Bayesian network al orithm. By treating the entire pedi-
gree as a directed acyclic graph (a Bayesian network), the genotype
of sample i depends on the genotypes of only his/her parents [27].
We can write the posterior probability as
Pr GDP,Dð Þ!Pni~1 Pr Di DGið ÞPr Gi DGfi ,Gmi
! " ð2Þ
The Bayesian network approach directly calculates the joint
probabilities for all the combinations of genotypes of the whole
family, and allows for analytic calculations for pedigrees with
inbreeding loops. The Bayesian network approach is straightfor-
ward and easy to implement; however, the computing time
increases exponentially when the pedigree size increases, so a
supplementary approach is needed for a larger pedigree.
Bayesian network parallelization. For variant calling using
whole genome sequencing data, there are billions of loci. After
filtering by FamSeq, there are still millions of candidate variant
positions remaining; thus, we propose to parallelize the Bayesian
network algorithm in order to reduce the computing time and
make this approach feasible in the DNA sequencing data analysis.
In the Bayesian network method, we need to calculate the
posterior probability for 3n kinds of genotypes. This amounts to a
large volume of homogeneous computing tasks that are suitable to
parallel computing by GPUs.
Compared to central processing units (CPUs), GPUs have many
advantages in parallel computing. A GPU usually has hundreds or
thousands of core processors, while there are only several core
processors for a CPU. Although the computing speed for each core
processor of a GPU (about 1 GHz) is not as fast as that of a CPU
(about 3 GHz), the total computing speed of a GPU is faster than
that of a CPU. For a large amount of homogeneous computing
tasks, we can assign one task to each GPU core to parallelize the
computing.
In FamSeq, we use CUDA (version 5.0 or later) to parallelize
the Bayesian network algorithm on a GPU. CUDA is a parallel
computing platform and programming model developed by
NVIDIA. It can be implemented on many CUDA-enabled GPUs
(https://developer.nvidia.com/cuda-gpus). CUDA provides many
application programming interfaces that can be easily incorporat-
ed into C++ language. A brief illustration of GPU programming in
FamSeq is shown in Fig. 3. For more details on GPU program-
Figure 3. Illustration of GPU parallel computing in FamSeq. The
program can be divided into two parts: a serial part and a parallel part.
The serial part is processed in a CPU and the parallel part is processed in
a GPU. The program: 1. Prepare the data for parallel computing in a
CPU; 2. Copy the data from CPU memory to GPU memory; 3. Parallelize
the 3n jobs computing in the GPU, where n is the pedigree size; 4. Copy
the results from GPU memory to CPU memory; and 5. Summarize the
results in the CPU.
doi:10.1371/journal.pcbi.1003880.g003
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In the Bayesian network method, we need to calculate the posterior probability for 3n kinds of 
genotypes. This amounts to a large volume of homogeneous computing tasks that are suitable to 
parallel computing by GPUs. 
Compared to central processing units (CPUs), GPUs have many advantages in parallel 
computing. A GPU usually has hundreds or thousands of core processors, while there are only 
several core processors for a CPU. Although the computing speed for each core processor of a 
GPU (about 1 GHz) is not as fast as that of a CPU (about 3 GHz), the total computing speed of a 
GPU is faster than that of a CPU. For a large amount of homogeneous computing tasks, we can 
assign one task to each GPU core to parallelize the computing. 
Figure 3.3 Illustration of GPU parallel computing in FamSeq. The program can be divided into 
two parts: a serial part and a parallel part. The serial part is processed in a CPU and the parallel 
part is processed in a GPU. The program: 1. Prepare the data for parallel computing in a CPU; 2. 
Copy the data from CPU memory to GPU memory; 3. Parallelize the 3n jobs computing in the 
GPU, where n is the pedigree size; 4. Copy the results from GPU memory to CPU memory; and 
5. Summarize the results in the CPU. 
In FamSeq, we use CUDA (version 5.0 or later) to parallelize the Bayesian network 
algorithm on a GPU. CUDA is a parallel computing platform and programming model developed 
by NVIDIA. It can be implemented on many CUDA-enabled GPUs 
(https://developer.nvidia.com/cuda-gpus). CUDA provides many application programming 
interfaces that can be easily incorporated into C++ language. A brief illustration of GPU 
programming in FamSeq is shown in Figure 3.3. For more details on GPU programming in 
the pedigr e because then the pedigree cannot be dir ctly spli into
anterior and posterior parts. There are two methods to solve this
problem. First, we can cut the loops according to complex criteria
and obtain an approximate result [15,26]. Cannings et al.
suggested using another method to obtain the analytical results
[16]. However, their method has large memory requirements.
Bayesian network algorithm. By treating the entire pedi-
gree as a directed acyclic graph (a Bayesian network), the genotype
of sample i depends on the genoty es of only his/he pa ents [27].
We can write the posterior probability as
Pr GDP,Dð Þ!Pni~1 Pr Di DGið ÞPr Gi DGfi ,Gmi
! " ð2Þ
The Bayesian network approach directly calculates the joint
probabilities for all the combinations of genotypes of the whole
family, and allows for analytic calculations for pedigrees with
inbreeding loops. The Bayesian network approach is straightfor-
ward and easy to implement; however, the computing time
increases exponentially when the pedigree size increases, so a
supplementary approach is needed for a larger pedigree.
Bayesian network parallelization. For variant calling using
whole genome sequencing data, there are billions of loci. After
filtering by FamSeq, there are still millions of candidate variant
positions remaining; thus, we propose to parallelize the Bayesian
network algorithm in order to reduce the computing time and
make this approach feasible in the DNA sequencing data analysis.
In the Bayesian network method, we need to calculate the
posterior probability for 3n kinds of genotypes. This amounts to a
large volume of homogeneous computing tasks that are suitable to
parallel computing by GPUs.
Compared to central processing units (CPUs), GPUs have many
advantages in parallel computing. A GPU usually has hundreds or
thousands of core processors, while there are only several core
processors for a CPU. Although the computing speed for each core
processor of a GPU (about 1 GHz) is not as fast as that of a CPU
(about 3 GHz), the total computing speed of a GPU is faster than
that of a CPU. For a large amount of homogeneous computing
tasks, we can assign one task to each GPU core to parallelize the
computing.
In FamSeq, we use CUDA (version 5.0 or later) to parallelize
the Bayesian network algorithm on a GPU. CUDA is a parallel
computing platform and programming model developed by
NVIDIA. It can be implemented on many CUDA-enabled GPUs
(https://developer.nvidia.com/cuda-gpus). CUDA provides many
application programming interfaces that can be easily incorporat-
ed into C++ language. A brief illustration of GPU programming in
FamSeq is shown in Fig. 3. For more details on GPU program-
Figure 3. Illustration of GPU parallel computing in FamSeq. The
program can be divided into two parts: a serial part and a parallel part.
The serial part is processed in a CPU and the parallel part is processed in
a GPU. The program: 1. Prepare the data for parallel computing in a
CPU; 2. Copy the data from CPU memory to GPU memory; 3. Parallelize
the 3n jobs c mputing in the GPU, wher n is the pedigree size; 4. Co y
the results from GPU memory to CPU memory; and 5. Summarize the
results in the CPU.
doi:10.1371/journal.pcbi.1003880.g003
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C/C++, see the NVIDIA CUDA C Programming Guide (http://docs.nvidia.com/cuda/cuda-c-
programming-guide/index. html) 
 
3.3 Results 
We compared the computing time of the four different methods using real sequencing data 
with one million (1M) variants and a pedigree size that varied from 7 to 12. If there is no 
alternative allele at a position, this means that all individuals in the family have a homozygous 
reference genotype. If these positions are provided in the input VCF files, FamSeq will skip these 
positions and run joint calling on only the remaining potential variant positions. In order to 
estimate the actual computing time of FamSeq, we prepared a VCF file with 1M candidate variant 
positions as the input file. We tested the non-GPU version on a Linux server with Intel Xeon 
CPUs of 3.07 GHz. Only a single core of one CPU was used during testing. The GPU version 
was conducted on an NVIDIA Tesla M2090 with 512 cores of a 1.3 GHz GPU on a Linux server 
from Texas Advanced Computing Center (TACC). We used only one GPU during the 
comparison. 
Table 3.1 Time needed for computation using FamSeq at one million positions. 
7 8 9 10 11 12
E-S N CPU 13s 12s 15s 16s 22s 34s
N CPU 100,920s 129,030s 160,170s 177,740s 240,650s 296,600s
Y CPU 177,460s 233,490s 289,720s 362,630s 432,760s 496,750s
N CPU 242s 605s 2,003s 6,483s 23,404s 73,485s
N GPU* 2,472s(150s) 2907s(169s) 3,312s(239s) 3,856s(397s) 4,519s(946s) 6,452s(2,717s)
Y CPU 250s 902s 2,013s 6,731s 2,2078s 70,417s
Y GPU* 2,548s(150s) 2986s(170s) 3,123s(239s) 3,602s(399s) 4,396s(954s) 6,605s(2,726s)
PU: Processing Unit
E-S: Elston-Stewart algorithm
BN: Bayesian network algorithm
♯We only called 100,000 variants for MCMC. The time shown here is 10 times the time of calling 100,000 variants.
* The number in the parentheses is the GPU computing time.
Pedigree SizeMethod Loops PU
BN
MCMC♯
 
Table 3.1 shows the computing time for FamSeq based on using the CPU versus the GPU. 
The Elston-Stewart algorithm was the fastest among the four methods we used, and was the best 
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choice when there were no inbreeding loops in the pedigree. The presence of inbreeding loops in 
the pedigree requires the use of loop cutting technology before calculating the probability of the 
anterior and posterior parts, which leads to algorithm complexity, increased computing time, and 
an approximation of the results. A big advantage of the Elston-Stewart algorithm is that the 
computing time increases almost linearly with increases in the pedigree size. When the pedigree 
size is large (greater than 12), the Elston-Stewart algorithm is almost the only computationally 
feasible method, especially for analyzing whole genome sequencing data. 
Although the computing time for the Bayesian network algorithm increases exponentially 
when the family size increases, variant calling with this method can be completed in several hours 
for a pedigree with fewer than 10 individuals, based on whole genome sequencing data and 
assuming there are about 20 million candidate variant positions. When the pedigree size is small, 
the computing time difference between the Bayesian network algorithm and the Elston-Stewart 
algorithm is small. An advantage of the Bayesian network algorithm is that it can directly 
calculate posterior probabilities in pedigrees that have inbreeding loops. From Table 3.1, we show 
that the computing time for the Bayesian network algorithm is not affected by whether or not the 
pedigree has inbreeding loops. 
We implemented the Bayesian network algorithm in both a CPU and GPU. Although we tried 
to increase the computing speed by parallelization at the GPU, the GPU version was slower than 
the CPU version when the pedigree size was less than 10. We found that transferring data 
between a CPU and GPU (steps 2 and 4 in Figure 3.3) requires a lot of time and becomes a 
bottleneck for speed improvement with GPU parallelization. The number in the parentheses in 
Table 3.1 is the actual GPU computing time, which is only about one tenth of the total computing 
time. Since the time required to copy the data increases linearly and the computing time increases 
exponentially, the advantage in speed improvement for GPU parallelization becomes evident 
when the pedigree size is larger than 10. When the pedigree size was 12, the GPU version became 
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10 times faster than the CPU version, which made it feasible to call variants for the whole 
genome sequencing data in ~36 hours as compared to more than 16 days for the CPU version. 
The actual improvement achieved from GPU computing will depend on its capacity, such as the 
total number of cores available in the GPU, which will vary from hundreds to thousands. 
We ran FamSeq-GPU on a personal computer, a MacBook Pro with OS X 10.8.5, which has 
an NVIDIA GeForce GT 650M GPU containing 384 CUDA cores of up to 900 MHz. When the 
family size was 7, the corresponding GPU computing time was 360 s, which almost doubled the 
time needed by the TACC GPU server (Table 3.1), and the total computing time, including 
reading and writing between the CPU and GPU, was 3,060 s. We further observed that the GPU 
computing time increased to 1,970 s and the overall time increased to 7,300 s for a family size of 
11. Our result shows if users do not have a professional computer server, they have an option of 
running FamSeq with parallel computing on a personal computer. 
We also tested the computing time for our MCMC algorithm under the same settings (Table 
3.1). Here, we set the total number of iterations at 20,000n, where n is the pedigree size. This 
option was the most time consuming and only provided approximate results. However, it can be 
used to analyze pedigrees with inbreeding loops and to incorporate uncertainty in the estimated 
alternative allele frequency, which is often not given as a set value, but as a value that follows a 
Beta distribution57. 
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4. Germline Mutation Detection with Next Generation Sequencing Data from 
Multiple Platforms  
4.1 Introduction  
Next generation sequencing technology has been developed for 10 years since the first next 
generation sequencing platform Roche/454 occurred in 20056. During the 10 years, many 
different kinds of next generation sequencing platforms have been developed, such as 
ABI/SOLiD7, Illumina/Solexa8,9, Life Technology Ion Torrent10,11 and Pacific Biosciences 
PacBio12. For these platforms, they used different strategies to sequence the DNA. During 
template preparation, Roche/454 and Life Technology Ion Torrent platforms use emulsion PCR64 
to get enough short reads while the Illumina/Solexa platform uses solid-phase amplification65. 
After the template preparation, 100 – 200 million of clonally amplified templates are created. In 
each template, there are many same DNA molecules. In Pacific Biosciences PacBio platform, the 
templates are prepared without amplification. For each template, there is only one molecule10,29. 
To get the sequence information during DNA synthesis, most platforms use fluorescent 
dyelabeled nucleotides to generate light signals and use a camera to catch the signals. Life 
Technology Ion Torrent used a different method. It measures the voltage change in the well in 
which there is a bead containing the DNA template during DNA synthesis. The read length of 
these platforms is also different. The read length of ABI/SOLiD platform is only 35-75bp, while 
the read length of PacBio platform could be over 10Kb.  
There are so many differences among these platforms. Their dominant error type is also 
different (Table 4.1).  For each platform, it has its own strengths and weakness. For a single 
platform, it may always produce the same platform error during variant calling even we control 
the data quality and increase the read coverage because of the platform’s special error type. If we 
combine the sequencing data from two or multiple platforms, we can correct some variant calling 
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errors by borrow the strength of advantage part of each other. Since the error type of each 
platform is different, we can assume the platform errors are independent for different platforms. 
When there is a variant calling error at a position in one platform, the other platform might give a 
high confident call to correct this error.  
Table 4.1 Overview of major next generation sequencing platforms29,31,66,67. 
Platform Amplification 
Read 
Length 
Sequence by 
Synthesis 
Throughput 
per run 
Run 
time 
Dominant 
error type 
Overall 
error 
rate 
Roche/454 Emulsion PCR 
400~1000
bp Pyrosequencing ~700 Mb 23 h Indel 0.50% 
ABI/ 
SOLiD 
Emulsion 
PCR 50~100bp 
Sequencing-by-
ligation ~100 Gb 10 d Substitution 0.10% 
Illumina/ 
Solexa 
Bridge 
PCR 35~250bp 
Reversible 
terminators 10~600Gb 3~12 d Substitution 0.20% 
Ion Torrent Emulsion PCR 35~200bp 
Ion semiconductor 
sequencing ~10 Gb 4 h Indel 1% 
PacBio NONE 250bp~10Kb 
Single molecule 
sequencing 5 Gb 2 d Indel 15% 
 
In the past 10 years, some platforms have faded away, such as Roach/454 platform. A lot of 
data has been generated from these platforms. Some of these platforms are not widely used now. 
People usually focus on the latest technologies and platforms to sequence the individuals, even 
though some individuals have been sequence before by old platforms. For example, the individual 
NA12878 in 1000 genome project has been sequenced over 10 times with different platforms32. If 
we can combine the data from the old platforms to generate the result with comparable accuracy 
rate as the current platforms, we can save a lot of money and time.  
We developed a method with Bayesian hierarchical model68 to combine the next generation 
sequencing data from multiple platforms. In this method, we assumed that the platform error for 
each platform is independent. There are some features that decide the probability of platform 
error at different positions for each platform. The training data were used to estimate the 
parameters in the model. With the estimated parameters, we validated the method in testing data. 
In simulation, we investigated the factors that might influence the accuracy of the model, 
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including sample size, platform error rate, coverage depth, correlation between features and 
likelihood. The investigation showed the guidelines to multi-platform variant calling in real data. 
We also validated our method in real next generation sequencing data. We collected next 
generation sequencing data of NA12878 in 1000 genome project from two most popular 
platforms: Illumina Miseq platform and Life technology Ion Torrent platform. The sequence calls 
with high confidence for NA12878 provided by Zook et al.32 were used as the true genotype in 
parameter estimation and model validation. In both simulation and real data, the method reduced 
the error rate of variant calling comparing to the single platform method when there are over 20 
platform errors in both two platforms in training data set.  
 
4.2 Method 
4.2.1 Single Platform Variant Calling. For variant calling, let Di denote the raw sequencing 
measurs at position i, such as read counts, read quality, mapping quality, etc. Gi denote the 
genotype at position i. The genotype at position i  is called by estimating the posterior probability 
Pr(Gi|Di). Following Bayes’ rule, the posterior probability is calculated as Pr(Gi|Di)
Pr(Di|Gi)Pr(Gi). Pr(Di|Gi) is the likelihood at  position i. The prior Pr(Gi) is the genotype 
frequency in population. 
 
4.2.2 Multi-platform Variant Calling. When there are sequencing data from 2 or more platforms, 
similar to the single platform variant calling, we can call the variant by estimating the posterior 
probability Pr(Gi|Di,1,Di,2,··· ,Di,j,··· ,Di,m), where Di,j is the raw sequencing measurements at 
position i from platform j, if there are total m platforms. Without loss of generality, we will use 
two-platform variant calling as an example. We write the model as following: 
 (4.1) 
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2.1. Single Platform Variant Calling. For variant calling in a single platform, let Di denote
the raw sequencing measurements at position i, such as read counts, read quality, mapping
quality, and etc. Gi denotes the genotype at position i. We can call the genotype at position
i by estimating the posterior probability Pr (Gi|Di). By following Bayes’ rule, the posterior
probability is calculated as Pr (Gi|Di) / Pr (Di|Gi) Pr (Gi). Pr (Di|Gi) is the likelihood, which
is estimated from the quality of each read mapped to position i. The prior Pr (Gi) is the genotype
frequency in population.
2.2. Multi Platform Variant Calling. When there are sequencing data from 2 or more plat-
forms, it is similar to variant calling in single platform. We need to estimate the posterior prob-
ability Pr (Gi|Di,1, Di,2, · · · , Di,j , · · · , Di,m), where i,j is the raw sequencing measurements at
position i from platform j. Without loss of generality, we will use two platform variant calling
as an example. We can write the model as following:
Pr (Gi|Di,1, Di2) / Pr (Di,1, Di,2|Gi) Pr (Gi) (1)
Assuming the sequencing measurements of the two platform are independent given the geno-
type, equation 1 can be rewritten as:
Pr (Gi|Di,1, Di2) / Pr (Di,1, Di,2|Gi) Pr (Gi)
= Pr (Di,1|Gi) Pr (Di,2|Gi) Pr (Gi)
(2)
1
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Assuming the sequencing measurements of the two platforms are independent given the 
genotype, equation 4.1 can be rewritten as : 
 (4.2) 
 
In single platform variant calling, we usually assume the sequencing measurements reflect the 
true genotype without considering the platform error (Figure 4.1A). Here we introduce a latent 
variable Z to the model. If there is a platform error in the platform, Z = 1. Otherwise, Z = 0. Then 
for each platform we have 
 (4.3) 
Zi,j is latent variable at position i for platform j, ! ∈ ! 1, 2 . If Z = 0, there is no platform error, the 
sequencing measurements reflect the true genotype. Pr(Di,j |Gi, Zi,j = 0) is the likelihood. When Z 
= 1, the platform fails. The sequencing measurements do not come from the true genotype GT, but 
from another genotype ! (Figure 4.1B). We used two models to represent the platform error. To 
simplify the problem, we only considered two alleles in each position: reference allele R and 
alternative allele A. There are three kinds of genotypes: RR, RA and AA, coded as 0, 1 and 2.  
Figure 4.1 Error model illustration. 
In the first model, the sequencing measurement is independent of the true genotype. The 
reads could come from any of the three genotypes with equal probability. In this case, we have 
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Figure 1. Model Illustration
In the single platform variant calling, we usually assume the sequencing measurements reflect
the true genotype without considering the system error (Figure 1A). Here we introduced a latent
variable Z into the model. If there is a system error in the platform, Z = 1. Otherwise, Z = 0.
Then for each platform we have
Pr (Di,j |Gi) = Pr (Di,j |Gi, Zi,j = 1)Pr (Zi,j = 1) + Pr (Di,j |Gi, Zi,j = 0)Pr (Zi,j = 0) (3)
Zi,j is the latent variable at position i for platform j. j 2 {1, 2}. If Z = 0, there is no system error,
the sequencing measurements reflect the true genotype. Pr (Di,j |Gi, Zi,j = 0) is the likelihood.
When Z = 1, the platform fails. The sequencing measurements do not come from the true
genotype GT , but from another genotype G˜ (Figure 1B). We suggested two models to simulate
the system error. In order to simplify the problem, we only considered two alleles in each position:
reference allele R and alternative allele A. There are only three kinds of genotypes: RR, RA and
AA, coded as 0, 1 and 2. In the first model, the sequencing measurement is independent of the
true genotype. The reads could come from any of the three genotypes will same probability. In
this case, we have
Pr (Di,j |Gi, Zi,j = 1) =
2X
k=0
Pr
⇣
Di,j |G˜i,j = k
⌘
Pr (G˜i,j = k)
=
1
3
2X
k=0
Pr
⇣
Di,j |G˜i,j = k
⌘ (4)
G˜i,j is the genotype that the reads generated from when there is a system error at position
i in platform j. In the second model, we assumed that the reads are generated from the other
two kinds of genotypes but the true genotype.
G~
Error
GT
GT
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No Error
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 (4.4) 
!!,! is the genotype that the reads are generated from when there is a platform error at position i 
in platform j.  
In the second model, we assume that the reads are generated from the other two kinds of 
genotype but the true genotype.  
 
 (4.5) 
 
Pr(Zi,j = 0) + Pr (Zi,j = 1) = 1. Here we assume the latent variable depends on some features of 
the platform, such as read depth, mapping quality and length of homopolymer.  For example, the 
main error type in Ion Torrent platform is InDel31, which is caused by homopolymer. The error 
rate increases according to the length of homopolymer10.  Logistic model is used to imitate the 
relationship between the latent variable and features:!Pr!(Z!,! = 1) != ! !"#!(!!! !!!!!,!!)!!!"#!(!!! !!!!!,!!). Fi,j is a 
vector indicating the features related to the latent variable at position i for platform j. α and β are 
the coefficients. 
 
4.2.3 Coefficients Estimation. If we know the latent variable Z at each position, we can use 
logistic regression to get the coefficients directly. However, we cannot get the latent variable 
directly. Instead, we use the training data with true genotype to estimate the coefficients through 
Markov chain Monte Carlo (MCMC) with Metropolis Hastings algorithm. Suppose the training 
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the system error. In order to simplify the problem, we only considered two alleles in each position:
reference allele R and alternative allele A. There are only three kinds of genotypes: RR, RA and
AA, coded as 0, 1 and 2. In the first model, the sequencing measurement is independent of the
true genotype. The reads could come from any of the three genotypes will same probability. In
this case, we have
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G˜i,j is the genotype that the reads generated from when there is a system error at position
i in platform j. In the second model, we assumed that the reads are generated from the other
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Pr (Di,j |Gi, Zi,j = 1) =
X
G˜i,j 6=Gi
Pr
⇣
Di,j |G˜i,j
⌘
Pr (G˜i,j)
=
1
2
X
G˜i,j 6=Gi
Pr
⇣
Di,j |G˜i,j
⌘ (5)
Pr (Zi,j = 0) + Pr (Zi,j = 1) = 1. We assume the latent variable depends on some features of
the platform. Pr (Zi,j = 1) =
exp (↵j+ jFi,j)
1+exp (↵j+ jFi,j)
. Fi,j is a vector indicating the features related to
the latent variable at position i for platform j. ↵ and   are the coe cients.
2.3. Coe cients Estimation. If we know the latent variable Z at each position, we can use
logistic regression to get the coe cients directly. However, usually we cannot get the latent
variable. Instead, if we have training data with true genotype we can estimate the coe cients
through Markov chain Monte Carlo (MCMC) with Metropolis Hastings algorithm. Suppose
the training data has n positions. GTi,j is the true genotype at position i for platform j. Let
GTj = [GT1,j , GT2,j , · · · , GTn,j ], and Fj = [F1,j ,F2,j , · · · ,Fn,j ]. Assume the system errors are
independent with each other at di↵erent positions, we have
Pr (↵j , j |GTj ,Fj ,Dj) = Pr (Dj |↵j , j ,GTj ,Fj) Pr (↵j , j ,GTj ,Fj)
/ Pr (↵j , j)
nY
i=1
Pr (Di,j |↵j , j , GTi,j , Fi,j)
/ Pr (↵j , j)
nY
i=1
0@ X
Zi,j=0,1
Pr (Di,j |GTi,j , Zi,j) Pr
 
Zi,j |↵j , j , Fi,j
 1A
(6)
Here ↵j and  j are priors. We assume they are independent with each other.
Pr (↵j , j) = Pr (↵j)
pjY
k=1
Pr ( k,j)
↵j ⇠ N(0, 100)
 k,j ⇠ N(0, 100)
(7)
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data has n positions. GTi,j is the true genotype at position i. Let GT = [GT1, GT2,··· ,GTn], and Fj = 
[F1,j, F2,j, ···, Fn,j]. Assume the platform errors are independent at different positions, we have 
 
 (4.6) 
 
To simplify the model, the prior distribution of the coefficients αj and βj are assumed to 
follow a normal distribution and are independent with each other: 
 
 (4.7) 
 
Suppose there are pj features related to the latent variable. According to the formula above, we 
adopted Metropolis-Hastings algorithm to estimate the parameters. During MCMC, we set burn-
in as 10,000 and the iteration times as 100,000. 
Figure 4.2 Illustration of data simulation.  
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Then we can select the features according to Pr ( k,j = 1) for each feature.
2.5. Data Simulation. The data is simulated according to the process illustrated in (Figure 2).
The true genotype at position i in platform j is simulated according to minor allele frequency
(MAF). Pr (GTi = RR) = (1 MAF)2, Pr (GTi = RA) = 2 ⇤MAF(1 MAF), and
Pr (GTi = RR) = MAF
2. The reads for each position are generated according to the system
error at that position. The system error depends on the features.
MAF
0.2 GT
G~
Z
F ~ normal
Read
Counts
error rate of reads
0.01
Likelihood
DP ~ Pois
binomial
Z = 1
Z = 0
GT
Figure 2. Illustration of data simulation
For platform j, Fi,j with pj features at position i is simulated according to a multi-variant
normal distribution N(0,⌃). ⌃ is the covariance matrix. The latent variable Zi,j is simulated
from the distribution Pr (Zi,j = 1) =
exp (↵j+ jFi,j)
1+exp (↵j+ jFi,j)
with specified ↵j and  j .
First we simulated the basic scenario. In the basic scenario, 2 features were related to the
system error in platform 1 and 3 features were related to the platform 2. The features at
position i is simulated from multivariate normal distribution N (0, diag(1, 1)) in platform 1 and
from N (0, diag(1, 1, 1)) in platform 2. We set ↵1 =  8.89,  1 = [1.5, 3.0]T for platform 1
and ↵1 =  7.90,  1 = [1.06, 1.59, 2.12]T for platform 2. The system error rate for the two
platform is all about 1%. The latent variable Zi,j is simulated according to Pr (Zi,j = 1) =
exp (↵j+ jFi,j)
1+exp (↵j+ jFi,j)
. The MAF is set to 0.2 to simulate the genotype and the average read depth
for each platform is set to 40 to simulated the read counts for each platform. Then we changed
average system error rate, read depth and covariance between the features for each platform to
check their influences to our method. In the previous simulation, the features are assumed to
be independent of likelihood. However, in the next generation sequencing data, most features
are related to the likelihood, which may influence the convergence and accuracy of MCMC.
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4.2.4 Data Simulation. The data is simulated according to the process illustrated in Figure 4.2. 
The true genotype at position i in is simulated according to minor allele frequency (MAF).   
Pr(GTi =RR)=(1−MAF)2, Pr(GTi =RA)=2∗MAF∗(1−MAF), and Pr(GTi = RR) = MAF2. The reads 
for each position are generated according to the platform error at that position. The platform error 
depends on the features. 
For platform j, Fi,j with pj features at position i is simulated according to a multi-variant 
normal distribution N(0,Σ). Σ is the covariance matrix. The latent variable Zi,j is simulated from 
the distribution Pr!(Z!,! = 1) != ! !"#!(!!! !!!!!,!!)!!!"#!(!!! !!!!!,!!)!with specified αj and βj. 
First we simulated the basic scenario. In the basic scenario, 2 features were related to the 
platform error in platform 1 and 3 features were related to the platform 2. The features at position 
i is simulated from multivariate normal distribution N(0, diag(1, 1)) in platform 1 and from N(0, 
diag(1, 1, 1)) in platform 2. We set α1 = −8.89, β1 = [1.5, 3.0]T for platform 1 and α2 = −7.90, β2 = 
[1.06,1.59,2.12]T for platform 2. In the basic scenario, the platform error rates for both two 
platforms are about 1%. The latent variable Zi,j is simulated according to Pr!(Z!,! = 1) !=! !"#!(!!! !!!!!,!!)!!!"#!(!!! !!!!!,!!). MAF is set to 0.2 to simulate the genotype and the average read depth for each 
platform is set to 40 to simulated the read counts for each platform. Then we changed average 
platform error rate, read depth and covariance between the features for each platform to check 
their influences to our method. In the previous simulation, the features are assumed to be 
independent of likelihood. However, in the next generation sequencing data, many features are 
related to the likelihood, which may influence the convergence and accuracy of MCMC. Instead 
of using features that are independent of likelihood to decide the latent variable Z, we added read 
depth with high correlation with likelihood as a feature influencing the latent variable Z. In 
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platform 1, the latent variable Zi,1 is decided by Pr !!,! = 1 = ! !"#!(!!".!!!.!!!!,!! !.!"!"!,!!)!!!!!"#!(!!".!!!.!!!!,!! !.!"!"!,!!),  
while Zi,2 is decided by        Pr !!,! = 1 = ! !"#!(!!".!!!.!"!!!,!! !.!"!!!,!!!.!"!"!,!!)!!!!!"#!(!!".!!!.!"!!!,!! !.!"!!!,!!!.!"!"!,!!).  
If Zi,j = 0, there was no platform error. The reads were generated from the true genotype GTi. 
Otherwise, !!,! was randomly generated from three kinds of genotypes in model 1 and was 
randomly generated from the other two kinds of genotypes but the true genotype is model 2. After 
we got !!,!, the reads were simulated from it. First, we simulated the read depth di,j from a 
poisson distribution Pois(λ = DPj). If !!,! = RR, the reference allele count dri,j was simulated from 
a binomial distribution B(di,j, 1 − e). e is error rate of reads. The count of alternative allele is 
calculated by dai,j =di,j −dri,j. If !!,! = AA, dri,j was simulated from B(di,j, e). When !!,! = RA, dri,j 
was simulated from B(di,j, 0.5). 
Since the allele counts were simulated from binomial distribution, we could calculated the 
likelihood from the binomial model: 
 
 (4.8) 
 
 
4.2.5 Real Data Preparation. In order to validate our method, we also applied the method in real 
data. We downloaded fastq file of sequencing data for individual NA12878 from two platforms: 
IonProton Ion PI v2 and HiSeq2000. The IonProton data is whole exome sequencing data with 
average read depth of 80 and the HiSeq data is whole genome sequencing data with average read 
depth of 70. To combine the sequencing data from the two platforms, we only consider the whole 
exome region given in the bed file of IonProton data. The short reads from IonProton and HiSeq 
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Instead of using features that are independent of likelihood to decided the latent variable Z,
we added read depth as a feature influencing the latent variable Z. In platform 1, the latent
variable Zi,1 is decided by Pr (Z1,j = 1) =
exp ( 27.8+1.5F1,j1+0.47DPi,j)
1+exp ( 27.8+1.5F1,j1+0.47DPi,j) , while Z2,j is decided
by Pr (Z2,j = 1) =
exp ( 21.6+1.06F1,i,j+1.59F2,i,j+0.34DPi,j)
1+exp ( 21.6+1.06F1,i,j+1.59F2,i,j+0.34DPi,j) .
If Zi,j = 0, there was no system error. The reads were generated from the true genotype
GT. Otherwise, G˜i,j was randomly generated from three kinds of genotypes in model 1 and is
rand mly gene ated from the other two kinds of genotypes but the true genotype i model 2.
After we got G˜i,j , the reads were simulated from it. First, we simulated the read depth di,j from
a poisson distribution Pois(  = DPj). If G˜i,j = RR, the reference allele count dri,j was simulated
from a binomial istribution B(di,j , 1  e). e is error rate of reads. The alternative allele count,
dai,j = di,j   dri,j. If G˜i,j = AA, dri,j was simulated from B(di,j , e). When G˜i,j = RA, dri,j was
simulated from B(di,j , 0.5).
Since the allele counts were simulated from binomial distribution, we could calculated the
likelihood from the binomial model:
Pr (Di,j |G) =
8>>><>>>:
  di,j
dri,j
 
(1  e)dri,j edi,j dri,j G = RR  di,j
dri,j
 
0.5di,j G = RA  di,j
dri,j
 
edri,j (1  e)di,j dri,j G = AA
2.6. Real Data Preparation. In order to validate our method, we also applied the method
in real data. We downloaded fastq file of sequencing data for individual NA12878 from two
platforms: IonProton Ion PI v2 and HiSeq2000. The IonProton data is whole exome sequencing
data with average read depth of 80 and the HiSeq data is whole genome sequencing data with
average read depth of 70. To combine the sequencing data from the two platform, we only
consider the whole exome region given in the bed file of IonProton data. The short reads from
IonProton and HiSeq were mapped to human genome reference of GRCH37 with TMAP and
bwa respectively. After mapping, we processed the data following GTAK best practice. Zook
et al. integrated 14 human genome sequencing data of NA12878 and provided a high confident
sequ ncing data for NA12878. We dow loaded the high confident sequencing data and us d
it as the truth. In the intersection region of whole exome and high confident truth, there are
32,874,214 homo-reference positions and 21,663 variant positions after filtering out the positions
with read depth less than 10 and 3 variant positions with more than 2 kinds of alleles. We
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were mapped to human genome reference of GRCH37 with TMAP 
(https://github.com/iontorrent/TS/tree/master/Analysis/TMAP) and bwa69 respectively. After 
mapping, we processed the data following GTAK best practice14. Zook et al.32 integrated 14 
human genome sequencing data of NA12878 and provided a high confident variant data for 
NA12878. We downloaded their data and used it as the truth. In the intersection region of whole 
exome and high confident truth, there are 32,874,214 homo-reference positions and 21,663 
variant positions after filtering out the positions with read depth less than 10 and 3 variant 
positions with more than 2 kinds of alleles. We compared the variant call from the two single 
platforms with the truth. At 32,871,024 positions (99.93% of total positions) both the two 
platform data were called as homo-reference. The real data is highly unbalanced. To balance the 
data, we randomly chose 20,163positions from the 32,871,024 positions and kept all the other 
positions to build the real data set. In the real data set, there are 21,663 variant positions and 
23,353 homo-reference positions. Among these 45,016 positions, HiSeq2000 has 140 different 
variant calls with single platform method comparing to the truth, while there are 4988 different 
variant calls for IonProton Ion PI v2 data (Table 4.2). 
Table 4.2 Summary of comparison of IonProton PI v2 and HiSeq2000 to high confidence 
sequencing call of NA12878. 
 
We randomly divided half of the data as training data and the other half as testing data. The 
training data was used to estimate coefficients of features for the two platforms. In the testing 
data, we used the estimated coefficients to call variants with two-platform data and compared the 
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compared the variant call from the two single platforms with the truth. At 32,871,024 positions
(99.93% of total positions) both the two platform data were called as homo-reference. The real
data is highly unbalanced. To balance the data, we randomly chose 20,163positions from the
32,871,024 positions and kept all the other positions to build the real data set. In the real data
set, there are 21,663 variant positions and 23,353 homo-reference positions. Among these 45,016
posi i ns, HiSeq2000 has 140 di↵erent variant calls with single platform metho comp ri g to
the truth, while there are 4988 di↵erent variant calls for IonProton Ion PI v2 data (Table 1
). We randomly divided half of the data as training data and the other half as the testing
data. The training data was used to estimated coe cients of features for the two platforms. In
the testing data, we used the estimated coe cients to call variants with two-platform data and
compared the result with variant calls from one platform. In the testing data set, there are 59
single platform variant calls for HiSeq2000 and 2376 for IonProton Ion PI v2. Since there are
much more di↵erent varia t calls in IonProton data set than HiSeq2000 data set, we focused on
whether we could make improvement for platform HiSeq2000 with our method. We also changed
the sample size of training data t check whether it had similar result with the simulation data.
Table 1. Summary of Real Data
IonProton PI v2
Right Wrong
HiSeq2000
Right 39923 4953
Wrong 105 35
2.7. Features in Real Data. We collected 18 di↵erent features from the two VCF files for
HiSeq2000 data and IonProton PI v2 generated by GATK (Table 2). Only some of these features
are related to the system error. To simply the model, we developed an ad hoc method to select
the features. All the features were included in the model at first. Coe cients for each feature
were estimated through MCMC. After 100,000 times of iterations, we check the trace plot of
the coe cient for each feature. Some of them converged while the others did not. We only
remained the features that converged and continue the previous steps until the coe cient for all
the features converged.
! ! 57 
result with variant calls from one platform. In testing data set, there are 59 single platform variant 
calls for HiSeq2000 and 2376 for IonProton Ion PI v2 that are different with the high confidence 
variant calls. Since there are much more different variant calls in IonProton data set than 
HiSeq2000 data set, we focused on whether we could make improvement for platform HiSeq2000 
with our method. We also changed the sample size of training data to check whether it had similar 
result with the simulation data. 
 
4.2.6 Features in Real Data. We collected 18 different features from the two VCF files for 
HiSeq2000 data and IonProton PI v2 generated by GATK (Table 4.3). Only some of these 
features are related to the platform error. Here we developed an ad hoc method to select features. 
All features were included in the model at first. Coefficients for each feature were estimated 
through MCMC. After 100,000 iterations, we check the trace plot of the coefficient for each 
feature. Some of them converged while the others did not. We only remained the features that 
converged and continue the previous steps until the coefficient for all the remaining features 
converged. 
Table 4.3 Features collected from VCF files for the platforms IonProton PI v2 and HiSeq2000.  MULTI-PLATFORM VARIANT CALLING OF NEXT GENERATION SEQUENCING DATA 8
Table 2. Features Collected from VCF Files
Feature Data Type Description
CHROM Categorical Chromosome, 1-22, X, Y
POS Integer Position of the locus
dbSNP Boolean In dbSNP or not
REF Categorical Reference allele (A, T, C, G)
ALT Categorical Alternative allale (A, T, C, G, .)
QUAL Double -10*LOG10(ALT is wrong)
DP Integer Read depth
RDF Double Reference allele frequency RD/ DP
ADF Double Alternative allele frequency. AD / DP
ODF Double Other allele frequency. (DP-RD-AD) / DP
GQ Double Genotype quality
Dels Double Fraction of Reads Containing Spanning deletions
FS Double -10*log10(p-value of strand bias)
MQ Double Mapping quality
MQRankSum Double Rank Sum Test for mapping qualities
QD Double Variant confidence normalized by unfiltered depth of variant samples
ReadPosRandSum Rank Double Sum Test for relative positioning of REF
numHomo Integer Length of homopolymer
3. Result
3.1. Sample Size And System Error Rate. In the simulation, the sample size of testing
data is 20,000 to reduce the sample variation. We changed the sample size of training data to
check its influence to the result. Table 3 shows the estimated coe cients and error rate with 95%
confidence interval for di↵erent training sample size. The last column of Table ?? is the error
rate for variant calling with two platforms. If the called genotype is di↵erent from the truth,
we tagged it as an error. The error rate is the percentage of errors in the testing data. If we
only used the data from one platform, the error rate is 0.69% (0.57%, 0.82%) for platform 1 and
0.69% (0.58%, 0.81%) for platform 2 in model 1. In model 2, the error rate is 1.02% (0.88%,
1.16%) for platform 1 and 1.04% (0.88%, 1.18%) for platform 2. When the sample size is less
than 500, the estimated coe cients by MCMC are far from the truth and the error rate of two
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4.3 Results 
4.3.1 Sample Size And Platform Error Rate. In the simulation, we changed the sample size of 
training data to find out its influence to the result, while the sample size of testing data is always 
20,000 to reduce the result variation. Table 4.4 shows the estimated coefficients and error rate of 
variant calling with 95% confidence interval for different training sample size. The last column of 
Table 4.4 is the error rate of variant calling with two platforms. If the called genotype is different 
from the truth, we tagged it as an error. The error rate is the percentage of errors in the testing 
data. If we only used the data from one platform, the error rate is 0.69% (0.57%, 0.82%) for 
platform 1 and 0.69% (0.58%, 0.81%) for platform 2 in model 1. In model 2, the error rate is 
1.02% (0.88%, 1.16%) for platform 1 and 1.04% (0.88%, 1.18%) for platform 2. When the 
sample size is less than 500, the estimated coefficients by MCMC are far from the truth and the 
error rate of two platforms in larger or similar to the single platform. When the sample size is less 
than 500, there are about 5 or less platform errors occurring in the training data since we set the 
platform error as 1%. There is not enough information for MCMC to estimate the coefficients. 
When we checked the trace plots of MCMC, the Markov chain does not converge in some 
scenarios. When the training sample size is 1000, there about 10 platform errors in each platform. 
Even though the estimated coefficients are not very close to the truth, the error rate of variant 
calling for two platforms in smaller than the error rate of variant calling for single platform, 
especially for model 2. When the sample size is larger than 2000, the estimation is quite close to 
the truth and the error rate of variant calling of two platforms is only about 15% of the error rate 
of variant calling for single platform for both model 1 and model 2. 
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Table 4.4 Estimated coefficients and variant calling error rate with 95% confidence interval for 
different training sample size 
 
In real data, the overall platform error rate for different sequencing platform varies from 0.1% 
to 15%31. We changed the platform error rate from 10% to 0.1% to find out the sample size we 
need in training to estimate the coefficients accurately. Figure 4.3 shows the relationship between 
the error rate of two-platform variant calling and training sample size for different platform error 
rates. It seems that when there are about 10 errors in each platform in the training data, there is 
significant improvement for variant calling when we combine the two platforms together. When 
there are more than 20 errors in each platform, more errors help little to improve the variant 
calling accuracy. In the following simulation, we set the sample size of training data as 10,000 
and the error rate to 1% to make sure that we estimated the coefficients accurately. 
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Table 3. Estimated Coe cient and Error Rate with 95% Confidence Interval
for Di↵erent Training Sample Size
Sample Size ↵1  1,1  2,1 ↵2  1,2  2,2  3,2 Error Rate(%)
Truth -8.89 1.50 3.00 -7.90 1.06 1.59 2.12
Model 1
100
-1389
(-1830,-1021)
128
(-122,566)
276
(-117,848)
-1611
(-2076,-1177)
124
(-157,573)
158
(-167,626)
259
(-149,846)
1.38
(0.65,7.39)
200
-1319
(-1849,-15.5)
199
(-92.2,582)
401
(-48.3,798)
-1461
(-2212,-7.68)
137
(-242,573)
200
(-111,706)
312
( -99.9,793)
0.98
(0.43,2.47)
500
-643
(-1670,-8.07)
110
(-0.28,391)
236
(2.12,647)
-851
(-2014,-8.18)
120
(-54.6,489)
172
(0.11,551)
265
(1.14,746)
0.51
(0.095,1.05)
1000
-173
(-1328,-7.59)
22.2
(0.59,237)
67.4
(2.33,506)
-175
(-1401,-7.00)
28.0
(0.47,235)
39.7
(0.93,289)
56.9
(1.40,460)
0.20
(0.07,0.53)
2000
-22.8
(-13.8,-7.97)
4.63
(1.04,2.69)
8.11
(2.38,5.12)
-9.42
(-12.6,-7.20)
1.25
(0.52,2.42)
1.88
(1.17,3.13)
2.61
(1.52,3.68)
0.12
(0.067,0.20)
5000
-9.30
(-11.1,-7.97)
1.59
(1.17,2.16)
3.16
(2.53,3.99)
-8.41
( -9.96,-7.19)
1.13
(0.79,1.60)
1.68
(1.27,2.13)
2.29
(1.77,2.81)
0.11
(0.065,0.17)
10000
-9.06
(-10.1,-8.19)
1.54
(1.23,1.92)
3.05
(2.66,3.59)
-8.12
(-8.94,-7.36)
1.08
(0.82,1.37)
1.63
(1.33,1.94)
2.20
(1.90,2.50)
0.11
(0.07,0.17)
Model 2
100
-1156
(-1913,-10.6)
99.9
(-158,502)
213
(-57.1,736)
-1303
(-2151,-9.92)
87.6
(-222,521)
161
(-124,687)
194
(-106,720)
1.60
(0.20,3.39)
200
-617
(-1854,-8.11)
71.5
(-111,471)
144
(-69.9,592)
-711
(-2087,-8.05)
53.8
(-163,402)
112
(-80.9,729)
136
(-33.7,665)
0.95
(0.18,1.98)
500
-72.4
(-956,-7.83)
6.78
(0.38,85.5)
23.4
(2.18,225)
-93.0
(-1504,-6.82)
14.7
(-0.11,217)
9.87
(0.77,152)
20.9
(1.23,380)
0.30
(0.11,1.14)
1000
-11.0
(-18.6,-7.99)
1.83
(0.69,3.09)
3.80
(2.40,6.69)
-9.83
(-15.9,-6.79)
1.37
(0.53,2.64)
2.11
(0.85,4.37)
2.59
(1.40,4.32)
0.17
(0.11,0.29)
2000
-9.47
(-12.5,-7.70)
1.60
(0.93,2.48)
3.20
(2.33,4.41)
-8.58
(-11.8,-6.91)
1.19
(0.65,1.88)
1.79
(1.06,2.75)
2.25
(1.65,3.15)
0.16
(0.10,0.24)
5000
-9.11
(-10.5,-8.08)
1.53
(1.15,2.01)
3.08
(2.57,3.66)
-8.17
(-9.53,-7.24)
1.11
(0.79,1.41)
1.65
(1.28,2.04)
2.18
(1.76,2.67)
0.16
(0.11,0.22)
10000
-8.97
(-10.1,-8.02)
1.50
(1.24,1.78)
3.03
(2.60,3.52)
-8.02
(-8.93,-7.41)
1.08
(0.84,1.31)
1.63
(1.37,1.93)
2.15
(1.88,2.41)
0.16
(0.11,0.21)
method still makes a big improvement to decreased the error rate (Figure 4). In the following
simulations, we set the read depth to 40 for each platform to make sure that ultiple platform
variant calling method didn’t take advantage from doubled read depth.
3.3. Correlation Between Features. In real data, the features we selected to predict the
system error are usually correlated with each other, which may influences the estimation of
coe cients error rate. In order to find out the influences of the correlation and to check the
robustness of our method, we changed the covariance between the features in the simulation.
Both two features in the first platform and the last two features in the second platform were set
to be correlated. We changed the correlation coe cient of these two features in the two platforms
from 0 to 0.95 and kept all other parameters the same to check its influence to the error rate.
As it is shown in Figure 5, when correlation coe cient increases, the variant calling error rates
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Figure 4.3 The two-platform variant calling error rate with different training sample size for 
different platform error rates. Each line indicates different platform error rate. A) Model 1. B) 
Model 2.   
 
4.3.2 Read Depth. Read depth has a big influence to the variant calling of sequencing data. As the 
read depth increases, the error rate of variant calling usually decreases. When we combined the 
sequencing data from two platforms, it seemed that we doubled the read depth. To check whether 
the multi-platform variant calling method gets advantage from doubled read depth we changed 
read depth from 10 to 40 and compared multi-platform variant calling result with single platform 
result with read depth from 20 to 80. When the read depth is less than 20, the variant calling error 
rate decreases a lot when the read depth is doubled for single platform variant calling. The two-
platform method has a little lower variant calling error rate than the single platform method with 
doubled read depth. When the read depth is more than 30, there is little difference of variant 
calling error rate between single platform method and single platform method with doubled read 
depth, while two-platform method still makes a big improvement to decreased the variant calling 
error rate (Figure 4.4). In the following simulations, we set the read depth to 40 for each platform 
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to make sure that multi-platform variant calling method didn’t take advantage from doubled read 
depth. 
Figure 4.4 Variant calling error rate with different read depth.  
 
4.3.3 Correlation Between Features. In real data, the features we selected to predict the platform 
error are usually correlated with each other, which may influence the estimation of coefficients. 
In order to find out the influence of the correlation between features and to check the robustness 
of our method, we changed the covariance between the features in the simulation. Two features in 
the first platform and the last two features in the second platform were set to be correlated. We 
changed the correlation coefficient of these two features in the two platforms from 0 to 0.95 and 
kept all other parameters the same. As it is shown in Figure 4.5, when correlation coefficient 
increases, the variant calling error rates for both single platform and two platforms also increases. 
However, the variation of correlation coefficient does not change the trend that the two-platform 
variant calling error rate decreases when the number of platform errors for each platform 
increases to about 20 and there is little changes after that. 
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Figure 4.5 Variant calling error rate with different training sample size for different correlation 
coefficients between latent variable related features. Each line indicates the two-platform variant 
calling error rate with different correlation coefficients, while the dots on the right side of figure 
indicate the variant calling error rate for single platform. A) Model 1. B) Model 2. 
 
4.3.4 Likelihood Related Features. When calculating the likelihood Pr(D|G), many different 
factors are considered, such as read depth and mapping quality, while these features may be 
selected to predict platform error at the same time. Read depth was selected as a feature related to 
both platform error and likelihood to check whether likelihood related features would influence 
the accuracy of the model. In the simulation, the average read depth was set to 40 and the training 
sample size was set to 10,000. The variant calling error rate for the two-platform method is 
estimated as 0.25% (0.18%, 0.36%) for model 1 and 0.39% (0.30%, 0.58%) for model 2, while 
the error rate for the single platform is 0.7% (0.59%, 0.84%) for model 1 and 1.10% (0.90%, 
1.22%) for model 2. 
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Figure 4.6 Number of two-platform variant calling errors in real data with training sample size. 
The horizontal line shows the number of variant call errors for single platform HiSeq2000 data 
set. A) Model 1. B) Model 2. 
 
4.3.5 Real Data Validation. We include all the features in Table4.3 into the model and process the 
feature selection for each platform first. In HiSeq2000 platform, four features were selected: 
dbSNP, ADF, Dels and FS, while in IonProton PI v2 platform, there were also four kinds of 
features selected: dbSNP, ODF, Dels and numHomo. We include all the features in Table 4.3 into 
the model and process feature selection for each platform first. In HiSeq2000 platform, four 
features were selected: dbSNP, ADF, Dels and FS, while in IonProton PI v2 platform, the 
following features were selected: dbSNP, ODF, Dels and numHomo. In real data validation, we 
also changed training sample size from 100 to the number of all loci (22,508) in the training data 
set. The relationship between the variant calling error rate and the training sample size was shown 
in Figure 4.6. It seems that when there are less than 10 platform errors (training sample size less 
than 2000) in HiSeq2000 platform, we cannot estimate the parameters accurately. The variation 
of two-platform variant calling error rate is big. There is little improvement to combine the two 
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platforms. If there are more than 10 platform errors in platform HiSeq2000, there is improvement 
of combining the two platforms comparing to the single platform HiSeq2000. When there are 
over 20 platform errors in platform HiSeq2000, the estimated parameters are quite consisted with 
each other for different runs. The confidence interval is very narrow. We can get stable 
improvement when there are more than 20 platform errors for each platform. This result is similar 
to the result from the simulation. When we use all the training data to estimate the parameters, the 
number of variant calling error is 43, 27% of improvement comparing to the 59 variant calling 
error in HiSeq2000 data set. 
 
4.4 Discussion 
We have developed a variant calling method to integrate next generation sequencing data 
from different platforms with Bayesian hierarchical model. This method takes advantages of 
merit from one platform to overcome the weakness from another platform to reduce the error rate 
of variant calling. In both simulation and real data, our method performs better than the single 
platform method when we have enough training data. We identified the influence of training 
sample size, read depth, covariance between features and likelihood related features to the model 
with simulation. We also applied our method to the real sequencing data of NA12878 from the 
two most popular sequencing platforms: Illumina sequencing platform (HiSeq2000) and Ion 
Torrent platform (IonProton PI v2). The result shows that our method improves the accuracy for 
both platforms when we combine them together. 
The result in both simulation and real data shows that our method makes improvements when 
there are more than 10 platform errors for each platform. When the number of platform error is 
more than 20 for each platform, the improvements are significant. More platform errors over 20 
have very small improvements to reduce the variant calling error rate. That one platform has 
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many platform errors while the other have less than 10 platform errors does not help but might 
increase the variant calling error rate because the parameters estimated from the platforms with 
less errors might be far from the truth and causes more mistakes. 
Usually, we can increase the read depth to improve the variant calling accuracy. High read 
depth reduces the variation during reads sampling to decrease the variant calling error rate. 
However, it will not help a lot when read depth reaches some point (Figure 4.4). Especially when 
the platform error is independent of the read depth. We cannot reduce the platform error rate by 
increasing the read depth. Our method partially solves this problem by combining the sequencing 
data from two different platforms. The platform errors for different platforms are usually 
independent from each other. When a platform error happens on a locus in one platform, it is 
unlikely that there is another platform error on the same locus in another platform. In this case, 
we can use the information from the platform without the platform error at this locus to correct 
the platform error in another platform. If the two sequencing data sets are from the same platform, 
the platform errors are not independent with each other. There might be platform errors on the 
same locus for the two data sets. Our model makes little improvement in this situation. 
In our model, the read depth for the two platforms should be comparable or the read depth of 
the platform with lower read depth cannot be very small (less than 10). If the read depth for one 
platform is very small, it cannot provide the signal (likelihood ratio between the true genotype 
and other genotypes) strong enough to correct the platforms in the other platform with higher read 
depth. The result of two platform variant calling will mainly follow the platform with higher read 
depth. 
The features in the next generation sequencing data are usually correlated. Some features 
might be calculated from one or a few other features. In simulation, it seems that the correlation 
does not affect the estimation of the coefficients but increase the variant calling error rate for both 
single platform method and two-platform method. It is more complex in real data. The result 
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might not as good as in simulation. However, in real data validation, dbSNP and ADF are high 
correlated in HiSeq2000 platform (correlation coefficient = 0.85, p-value < 2.2e-16). Our method 
still works well when the correlation is not very high. 
The correlation between the features and likelihood is another problem we need to consider. 
The likelihood is calculated from some of the features. The likelihood has high correlation with 
these features. These features influence the variant calling error rate through both the platform 
error and likelihood. In simulation, we set read depth positive correlated with platform error. The 
platform error increases when we have higher read depth. While on the other hand, high read 
depth increases the signal to noise ratio (likelihood ratio between the true genotype and other 
genotypes) to give more accurate result. These two effects counteract with each other. That is 
why the two-platform variant calling result in this scenario (0.25% in model 1 and 0.39% for 
model 2) is high than in the basic scenario (0.11% in model 1 and 0.16% for model 2). 
Both the feature dbSNP and Dels are selected in HiSeq2000 and IonProton platform. As we 
know, variant calling is easier for common variants (in dbSNP) than rare variants. In our model, 
the negative coefficient indicates the probability of platform error decreases when the feature 
increases. That is why the coefficient estimated for dbSNP is negative for the two platforms. It is 
hard to call variants when there are many indels around, which explains the positive parameters 
of Dels in HiSeq2000. It is different in IonProton data set. In IonProton, the main cause of 
platform error is homopolymer. The longer the homopolymer is, the more likely there is a 
platform error. That is why numHomo is included in the IonProton data set and the parameter is 
position. But when indels are called, it will reduce the error of homopolyer. The parameter for 
Dels in IonProton is negative. There are usually two kinds of alleles at each locus. When there are 
more than two alleles, it has high possibility of a platform error like the feature of ODF in 
IonProton data set. The other two features selected in HiSeq2000 are ADF and FS. Their 
parameters are both positive. FS reflects the possibility of strand bias, which leads to platform 
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error. We are still investigating the reason why ADF in included in HiSeq2000 data set with 
positive parameters. 
There are 9 out of 14 platforms that Zook32 used to generate the high confidence variant calls 
coming from Illumina. According to Zook’s criteria, the high confidence variant calls have 
preference on Illumina data to be right. It partially explained the high variant calling error rate in 
the IonProton data set. If it is the truth, our method will have more than 27% of improvement for 
HiSeq2000 data set. 
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5. Estimating TP53 Mutation Carrier Probability in Families with Li-Fraumeni 
Syndrome Using LFSpro 
5.1 Introduction 
Li-Fraumeni syndrome (LFS) is an autosomal dominant inherited cancer predisposition 
syndrome. It was first described by Drs. Li and Fraumeni after they encountered unusual familial 
clustering of childhood soft tissue sarcomas with early onset breast and other cancers in relatives 
in four families70,confirmed in a survey of over 600 childhood rhabdomyosarcoma patients and 
their families71. In 1988 Li et al. summarized the findings in 24 kindreds identified by a proband 
with a sarcoma before age 45 years, a first degree relative with cancer in that age interval, and 
another close (first or second degree) relative in the lineage with either cancer before age 45 or a 
sarcoma at any age.  Using these criteria they identified the 6 most common tumors termed the 
component tumors including soft-tissue and bone sarcomas, breast cancer, brain tumors, leukemia 
and adrenal cortical carcinoma. These cancers occurring before age 45 accounted for almost 80% 
of all cancers in the 24 kindreds, and these criteria formed the basis for the classic LFS clinical 
criteria.   
In 1990, germline mutations in the tumor suppressor gene TP53 were identified in 5 out of 5 
families studied with LFS72. However, since then it has been shown that only 60-80% of ‘classic’ 
LFS families have TP53 germline mutations36. The lifetime cancer penetrance for carriers with 
TP53 mutation is about 90%33,34. For women, this penetrance increases to nearly 100% by age 70 
years, mostly because of breast cancer35. A recent study demonstrated that with clinical 
surveillance, which included whole-body and brain magnetic resonance imaging, people with 
TP53 mutations had significantly improved survival73. These findings indicate that early 
identification of TP53 mutation carriers is beneficial as cancer screening can significantly 
improve survival. 
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To date, several sets of clinical criteria have been developed to identify individuals with TP53 
mutations. The first criteria proposed, termed classic LFS criteria, has high specificity, but low 
sensitivity in the identification of patients carrying TP53 mutations37. Later, Birch74 and Eeles75 
introduced Li-Fraumeni-like syndrome criteria, which are more sensitive and include some but 
not all components of the classic LFS criteria. However, both the classic LFS and the Li-
Fraumeni-like syndrome criteria have bias in ascertainment and family selection38. To avoid this 
bias and allow for identification of TP53 mutation carriers with a negative family history (e.g., 
cases in which the proband has an unaffected parent carrying a TP53 mutation or the proband has 
a de novo TP53 mutation), Chompret et al. proposed alternative criteria to identify TP53 mutation 
carriers38,39. The Chompret criteria are more specific with respect to cancer type and age of onset 
and focuses more on the cancer information of the individual.  This can lead to a high false 
positive rate.  
The classic LFS and Chompret criteria are all widely used in clinical practice as guidelines to 
identify patients with LFS. However, these criteria focus on affected family members without 
considering healthy individuals in the family and therefore much of the family information is 
discounted.  In addition these criteria can only be applied to individuals and families with LFS 
spectrum cancers.  
To address these limitations, we developed LFSpro, which can estimate an individual’s TP53 
mutation probability on the basis of a detailed family history of cancer. LFSpro is built on a 
Mendelian risk prediction model40, which has been successfully used in PancPRO76 and 
MelaPRO77. To develop LFSpro, we introduced a de novo mutation rate into the original 
Mendelian risk prediction model to account for the relative frequent occurrence of de novo 
mutations in families with LFS78. We validated the performance of our model using 183 families 
prospectively collected at The University of Texas MD Anderson Cancer and 582 families from 
the International Sarcoma Kindred Study, Australia. We found that LFSpro had both higher 
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sensitivity and higher specificity in identification of TP53 mutation carriers compared to the 
classic LFS and Chompret criteria. 
 
5.2 Method 
5.2.1 Model Development.  LFSpro estimates the probability of any designated family member 
carrying a TP53 mutation on the basis of the penetrance of TP53 mutations and the detailed 
family history of cancer. The penetrance of TP53 mutations is defined as the probability of 
developing any cancer at each age35. We built LFSpro based on Mendelian risk prediction 
models40,76,77. The probability of an individual carrying a TP53 mutation is estimated via the 
following formula: 
Pr Gi |D,P( ) =
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Here !! denotes the genotype for individual i, !!! denotes genotypes for all individuals in the 
pedigree except individual i, !!" and !!" are the genotypes of individual j’s father and mother, !! denotes the phenotype of individual i, and P denotes the pedigree structure. Pr D|G  is 
likelihood that can be estimated from the penetrance. Pr !!|!!" ,!!"  denotes the transmission 
probability. To account for the substantial de novo mutation rate in LFS families, we incorporated 
a de novo mutation rate into the Mendelian risk prediction model. In other words, when both 
parents lack TP53 mutations, there is a small probability (2 times de novo mutation rate) that their 
child is a TP53 mutation carrier. During method validation, we used several different de novo 
mutation rates to check which rate was the best for our model. 
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It is computationally challenging to calculate the posterior probability from formula 1 
directly. Instead, we used the Elston-Stewart algorithm to calculate the posterior probability for 
extended families23. 
 
5.2.2 Validation Study Population The study population used to validate our method consisted of 
two different groups of patients. The first group comprised of childhood soft-tissue sarcoma or 
osteosarcoma patients (‘probands’) treated at The University of Texas M.D. Anderson Cancer 
Center (Houston, TX) from 1944 to 1983 and their extended families members. The details on 
data collection, frequencies of site-specific cancers and germline testing of these patients have 
been described previously33,34,79-81. These extended kindreds were prospectively followed up for 
more than 30 years. Medical records and death certificates were used to confirm reported cancers, 
where possible. For the current analysis we defined case subjects as affected only if diagnosed 
with malignant tumors, excluding non-melanoma skin cancers, but including all adrenal cortical 
tumors, choroid plexus tumors, ovarian granulosa tumors and breast carcinoma in situ.  Cancer 
diagnoses were further subdivided according to site: LFS spectrum (osteosarcomas, soft-tissue 
sarcomas, breast, brain, adrenal, lung and leukemia) and non-LFS spectrum cancers (prostate, 
colon, kidney, thyroid and others). Peripheral blood samples were collected from the probands 
and their relatives after gaining informed consent. Probands’ TP53 status was determined by PCR 
sequencing of exons 2-11. If TP53 mutation was identified, then testing was extended to all first-
degree relatives (both affected and unaffected with cancer) of the proband or any other family 
member found to have the familial mutation. This approach of extending the germline testing 
based on mutation status and not on phenotype of family members should not introduce an 
ascertainment bias during the analysis33,35. Individuals unavailable for testing (largely deceased) 
who were the links between confirmed mutation carriers were considered obligate mutation 
carriers.  In kindreds in which the proband was not found to have a TP53 mutation by sequencing, 
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no other family members were tested. This first group of patients (from here onwards referred to 
as ‘pediatric sarcoma’) consisted of 183 unrelated families with 2553 individual members (Table 
5.1). 11 of the kindreds included at least one individual with a confirmedTP53 mutation. Data 
from the other 172 TP53 negative families was used to assess whether LFSpro can control for the 
false positive rate in our model.   
Table 5.1 Overview of validation data sets by families. 
Yes No Yes No
11 172 19 563
1256 1297 591 16386
127(10.11%) 265(20.43%) 78(13.20%) 1788(10.91%)
19(1.51%) 0 7(1.18%) 165(1.01%)
7(0.56%) 0 8(1.35%) 48(0.29%)
Nindividual with Nprimary cancer = 2
Nindividual with Nprimary cancer > 2
Family with TP53 Mutation CarrierFamily with TP53 Mutation Carrier
adult-Sarcomapediatric-Sarcoma
NFamily
Nindividual
Nindividual with Nprimary cancer = 1
 
The second group consisted of a prospective cohort of adult-onset sarcoma patients and their 
extended families recruited to the International Sarcoma Kindred Study from six major sarcoma 
treatment centers across Australia. All reported cancer diagnoses were verified by reference to 
medical records, Australian and New Zealand cancer registries or death certificates82. The 
proband’s TP53 status was determined by PCR sequencing, high resolution melt (HRM) analysis 
and multiplex ligation-dependent probe amplification (MLPA) analysis to detect large deletions 
or genomic rearrangements82. This second group of patients (referred to as ‘adult sarcoma 
families’) consisted of 582 separate families with 16,977 individuals (Table 5.1).  19 of these 
kindreds had at least one individual with a confirmed TP53 mutation.  
 
5.2.3 Validation Study Design. The TP53 mutation carrier probability for the individuals with or 
without TP53 mutations was estimated using LFSpro. The receiver operating characteristic 
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(ROC) curve was used to evaluate the model discrimination. Both classic LFS and Chompret 
criteria were used to estimate whether each individual had a TP53 mutation. We then compared 
the results from LFSpro to the results from the classic LFS and Chompret criteria to evaluate our 
method.  
Figure 5.1 Illustration of time range of data collection for pediatric-sarcoma TP53 positive 
families. Data was collected since the proband of the families was first diagnosed with LFS-
spectrum cancer. 
5.2.4 Roll Forward. Most of the TP53-positive pediatric-sarcoma data have been collected over 
the course of 40 years (Figure 5.1). To evaluate our model works with limited pedigree 
information and to evaluate whether our model could predict LFS-spectrum cancers, we re-
arranged the validation population data by starting at the time when the proband was first 
diagnosed with an LFS-spectrum cancer and rolling forward every 10 years including only those 
individuals, their ages and their cancer affection status of that period.  At each roll forward time 
point, classic LFS criteria, Chompret criteria and LFSpro were used to assess the influence of 
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time on the carrier estimates. Because we did not have a long observation time for TP53-negative 
families, we only rolled forward the data for TP53-positive families 
 
5.3 Results 
5.3.1 Clinical Illustration. Several scenarios of a hypothetical pedigree were used to illustrate 
how LFSpro provides information to support clinical decisions by estimating TP53 mutation 
probability for counselees. In scenario 1 (Figure 5.2A), the TP53 mutation probability for the 
counselee estimated by LFSpro is 39.47%, while this probability is about 0.01% in general 
population. This mutation carrier probability increases when it is more likely a Mendelian 
transmission occurs in the pedigree. For example, if we exchange the status between the 
counselee’s grandmother and the grandmother’s sister (the counselee’s grandmother had breast 
cancer at age 18 while the grandmother’s sister was healthy at age 42, scenario 2, Figure 5.2B), 
the TP53 mutation probability for the counselee will increase to 77.78%. If more individuals in 
the family have cancer, the probability that the counselee is a TP53 mutation carrier also 
increases. If both the counselee’s grandmother and the grandmother’s sister have cancer (scenario 
3, Figure5.2C), the counselee’s probability rises to 89.94%. In the first three scenarios, it is likely 
that the TP53 mutation is transmitted from the counselee’s great grandmother to the counselee. 
The probability of de novo mutation is small. If the pedigree is as shown but the counselee’s 
grandmother is healthy at an advanced age and we exchange the status of the counselee’s mother 
and her aunt (scenario 4, Figure 5.2D), the probability that the grandmother is a TP53 mutation 
carrier is small. It is possible that there is a de novo mutation for the counselee’s mother. If we 
consider the possibility of de novo mutation and set the de novo mutation rate to 0.0005, the 
carrier probability is 48.8% for the counselee, while if we ignore the de novo mutation possibility 
the carrier probability is 0.5% (Table 5.2). Consideration of the de novo mutation rate therefore 
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can have a significant impact on the carrier probability. The results of application of the classic 
LFS and Chompret criteria for the counselee are also shown in Table 5.2.  
Figure 5.2 A hypothetical family pedigree to illustrate the clinical utility of LFSpro. An arrow 
points to the counselee, for whom the TP53 mutation probability is calculated by LFSpro on the 
basis of her family history of cancer. The sites of cancer onset are provided below each of the 
affected family relatives, together with the age in years at which the cancer was diagnosed. A-D) 
Four variations in clinical scenarios. 
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Table 5.2  Clinical illustration of LFSpro.  
By Age By Age Classic Chompret
40 Years 70 Years Criteria Criteria
General Populationb - 2.0% 21.9% - -
Shown in Fig 1A (Scenario 1) 39.5% 27.3% 47.1% N Y
Exchange the status of counselee's grandmother and 
the grandmother's sister (Scenario 2, Fig 1B) 77.8% 52.1% 80.5% N Y
Counselee's grandmother is also affected at age 42 
years (Scenario 3, Fig 1C) 89.9% 59.9% 91.2% N Y
0.5% 2.2% 13.0%
48.8% 33.3% 55.2%
a We set 0.0005 as the default for the de novo mutation rate. 
b SEER 2009-2011 data
c In Scenario 4, we calculated the carrier probability at de novo mutation rate = 0, for comparison.
YCounselee's grandmother is healthy at an andvanced age while her mother is affected (Scenario 4, Fig 1D)c
Counselee's Absolute
Risk of Developing
CancerCarrierProbabilitya
N
 
5.3.2 De Novo Mutation Rate. In LFSpro, we incorporated the de novo mutation rate into the 
Mendelian risk prediction model. Figures 5.3A, 5.4 and 5.4 show the influence of de novo 
mutation rate on the result. The area under the ROC curve (AUC) increases while the de novo 
mutation rate increases until the de novo mutation rate is about 0.0005 (Figure 5.3B), and then the 
AUC decreases. The observed expected ratio (OE ratio, the ratio between the number of observed 
TP53 mutation carriers and the summation of probability of TP53 mutations for all individuals 
estimated by LFSpro) is also close to 1 when the mutation rate is 0.0005. Therefore, we used 
0.0005 as the default de novo mutation rate in our study.  
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Figure 5.3. Validation results. A) Receiver operating characteristic (ROC) curves of LFSpro for 
data from 183 families collected through the pediatric sarcoma cohort, with de novo mutation rate 
changing from 0 to 0.0005. Also shown are results of applying the classic LFS and Chompret 
criteria to this data set. B) Influence of de novo mutation rate on observed/expected (O/E) ratio 
and area under the receiver operating characteristic curve (AUC). p-S: pediatric-sarcoma families. 
a-S: adult-sarcoma families. C) ROC curves of LFSpro for three data sets when we set the de 
novo mutation rate as 0.0005. Also shown are true positive and false positive rate of classic LFS 
and Chompret criteria for the three data sets. D) Part of the ROC curves of different roll forward 
time. RF: roll forward. LCD: last contact date.  
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Figure 5.4 ROC curves of LFSpro for adult-sarcoma families with de novo mutation rate 
changing from 0 to 0.0005. 
Figure 5.5 ROC curve of LFSpro with de novo mutation rate of 0.0005 for pediatric-sarcoma 
families. Variability is shown by 10 bootstraps. Also shown are true positive and false negative 
rate of classic LFS and Chompret criteria. The purple x indicates the cut-off we used to 
distinguish TP53-positive from TP53-negative individuals in LFSpro (posterior probability of 
TP53 mutations: 0.2). 
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5.3.3 Validation Result. Figure 5.3C presents the results of LFSpro with the results of both classic 
LFS and Chompret criteria for two data sets. The classic LFS criteria are very conservative. The 
false positive rate is almost 0, but its sensitivity is not very high. The sensitivity is only around 
10% for the two data sets. The Chompret criteria have much higher sensitivity but also a 
relatively higher false positive rate. For pediatric-sarcoma families, both the points of the classic 
LFS and Chompret criteria are under or on the ROC curve, indicating that LFSpro performs better 
than the classic LFS and Chompret criteria. For the adult-sarcoma families, the point of the 
Chompret criteria is a little higher than the ROC curve of LFSpro. Table 5.3 summarizes AUC 
and OE estimates by LFSpro and the 95% confidence intervals.  
Table 5.3 Summary of validation results 
AUC OE
p-Sarcoma 0.87(0.77,0.95) 0.96(0.74,1.20)
a-Sarcoma 0.69(0.57,0.81) 0.78(0.51,1.12)  
Table 5.4 Reclassification of TP53 mutation carriers using LFSpro. 
Pr≥0.2 Pr≥0.2 Pr≥0.2 Pr≥0.2
Classic
+ 4 0b 0 1a
- 21a 7 13b 235 3.20%
Chompret
+ 15 1b 3 15a
- 10a 6 10b 221 4.98%
Classic
+ 2 0b 1 0a
- 8a 15 39b 548 -5.06%
Chompret
+ 7 4b 11 37a
- 3a 11 29b 511 1.14%
c Reclassification rate = (total # of correcte reclassification - total # of incorrecte 
reclassification) / total # events
a LFSpro corrected classifications of carrier or noncarrier, as compared to clinical criteria.
b  The clinical criteria corrected classifications of carrier or noncarrier, as compared to LFSpro.
Reclassification ratec
p-Sarcoma
a-Sarcoma
Carriers Noncarriers
LFSpro
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We also compared 3 different methods in the reclassification table (Table 5.4). We used 0.2, 
which is the turning point in the ROC curve, as the cutoff to classify TP53-positive and TP53-
negative individuals in LFSpro (Figure 5.5). The reclassification rate was defined as the 
percentage of individuals whose classification by LFSpro differed from their classification by 
classic LFS or Chompret criteria. A positive value means that LFSpro makes a net improvement. 
For pediatric-sarcoma families, LFSpro performs better than both classic LFS and Chompret 
criteria. For adult-sarcoma families, LFSpro is better than the Chompret criteria, while the 
reclassification rate is negative when comparing to the classic LFS criteria. However, the 
sensitivity for the classic LFS criteria is too low (about 10%) which makes it difficult to detect 
TP53 mutations carriers in the population using the classic LFS criteria only.  
 
5.3.4 Roll Forward. Figure 5.3D shows how the results of LFSpro and the other two clinical 
criteria changed when we rolled forward the data for TP53-postive pediatric-sarcoma families. 
The false positive rate for the classic LFS criteria is always 0. The sensitivity of classic LFS 
criteria decreased initially and reached the lowest point when we rolled forward 30 years and then 
improved when we rolled forward 40 years (The true positive rate and false positive rate are the 
same for rolling forward 40 years and the last contact date). The sensitivity of the Chompret 
criteria increased smoothly as we had more family information. The AUC for LFSpro increased 
at first and then dropped when rolling forward 30 years and then increased again until the last 
contact date. At the 20 year and 30 year time point, Chompret criteria performed better than 
LFSpro. And at all other rolling forward time points, LFSpro performs better or as well as the 
Chompret criteria.  
 
 
! ! 81 
5.4 Discussion 
Our validation showed that in most cases LFSpro had both higher sensitivity and higher 
specificity than both the classic LFS and Chompret criteria, indicating that LFSpro provides a 
better method to identify the TP53 mutation carriers. 
Unlike the classic LFS and Chompret criteria, which only take into account the information 
about the counselee’s first and second degree relatives with cancer, LFSpro uses information 
from all family members. The information from the family members with cancers helped LFSpro 
to predict TP53 mutation carriers with high sensitivity, while the information about healthy 
family members prevented LFSpro from being associated with a high false positive rate. This was 
evident when we added TP53 negative families into the validation population. In many TP53 
negative families, the proband and close relatives had early onset of LFS-spectrum cancers, a 
significant predictor of TP53 mutations. This explains why the Chompret criteria classified the 
probands in such families as TP53 mutation carriers in error. In contrast, the inclusion of healthy 
family members (especially the parents) helped LFSpro to avoid these false positives.  
Whereas the classic LFS and Chompret criteria provide a binary result—i.e., to test or not to 
test for germline TP53 mutations—LFSpro provides a probability that a certain individual carries 
a germline TP53 mutation. We can change the cut-off for the probability to balance sensitivity 
and specificity. Another limitation of the classic LFS and Chompret criteria is prediction of TP53 
mutation carrier status only when the individual has had a LFS spectrum cancer. If the individual 
is healthy, the prediction of the classic LFS and Chompret criteria will always be non-carrier. 
However, LFSpro can give an estimation of the carrier probability even if the individual is 
healthy. 
The prevalence of de novo TP53 germline mutations have been reported to be at least 7% to 
as high as 20%41, which is  more substantial than previously appreciated. We found that when we 
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incorporated the de novo mutation rate into our model, the predictive power of the model 
improved substantially. AUC increased from 0.60 to 0.71 for pediatric-sarcoma families (Figure 
5.3A) and from 0.57 to 0.62 for all adult-sarcoma families (Figure 5.4) even though the mutation 
rate only increased from 0 to 10!!. The hypothetical illustration shows that there is not 
significant difference to incorporate de novo mutation when it is a Mendelian transmission. 
However, when there is negative family history or a true de novo mutation occurs, a big increase 
in carrier probability occurs, which underscores the importance of de novo during LFS analysis. 
According to the validation population of our study, 0.0005 seems to be a good estimation of the 
de novo mutation rate in LFS families. 
In the adult-sarcoma data set, the Chompret criteria is a little better than LFSpro (Figure 
5.3C). This may be due to the fact that Chompret criteria can identify a TP53 mutation carrier 
using only the information from that individual, rather than depending on strong family cancer 
history. However, this also allows for the Chompret criteria to result in many false-positives. In 
the TP53 positive adult-sarcoma families, there are 7 families with only 1 or 2 individuals with 
cancers. When we removed all these individuals and only considered the adult-sarcoma families 
with more than 2 individuals with cancers, LFSpro performed better than the Chompret criteria. 
Therefore, when family information is limited (< 3 individuals with cancer in the family), we can 
use the Chompret criteria to ensure that we do not miss any TP53 mutation carriers. In contrast, 
when family information is sufficient, it is better to use LFSpro to identify TP53 mutation carriers 
since LFSpro has higher sensitivity and specificity than the Chompret criteria.  
Another reason LFSpro does not perform as well as Chompret criteria is because in LFSpro, 
if a patient has more than 1 cancer, we consider only the first cancer in the calculation. However, 
in the Chompret criteria, one patient with multiple primary cancers is a very important criterion 
for identifying TP53 mutations. As previously reported, early onset of multiple LFS-spectrum 
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cancers is one of the characteristics of LFS83 Therefore, we plan to incorporate information about 
multiple primary cancers in a single individual into our model.  
In addition, in the roll-forward study of the TP53-positive pediatric-sarcoma families, 
LFSpro did not perform as well as the Chompret criteria when there was not enough family 
information.  The AUC of LFSpro increased first and then there was a drop at 30 years and then 
increased again (Figure 5.3D). This can be explained by the observation that when we rolled 
forward the years, we had more information about the existing family members and therefore we 
could make the estimation more accurately. After about 20 to 30 years a new generation was 
born, with most of them being healthy at first, which reduced the probability that they are TP53 
mutation carriers and this in turn reduced the probability that their first degree relatives are TP53 
mutation carriers. And during this period, some TP53 mutation carriers developed multiple 
cancers. The Chompret criteria used the information to improve the prediction.  
In summary, with the advent of population and clinic-based ascertainment of mutations in 
TP53 in the context of next generation screening strategies, new methods that incorporate de novo 
mutations will become increasingly relevant clinically. To address this need, we developed 
LFSpro and validated it with both TP53-positive and TP53-negative families. LFSpro provides an 
accurate estimate of TP53 mutation carriers on the basis of family history and de novo mutation 
rates. With more accurate identification of TP53 mutation carriers, we can initiate appropriate 
screening and health management thereby reducing disease burden and cancer mortality. 
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6. Conclusions and Future Research 
6.1 Conclusions 
In this dissertation, we focused on developing methods to improve the accuracy of germline 
mutation detection in next generation sequencing data and estimating the TP53 mutation carrier 
probability in families with Li-Fraumeni syndrome. We investigated the factors that influence the 
performance of our methods and validate the methods in both simulation and real data. The 
results show that the new methods improve the accuracy comparing to the existing methods. 
We first introduced the method, FamSeq, using pedigree information to improve the variant 
calling accuracy in Chapter 2. In simulation and real data, FamSeq reduces both false positive and 
false negative rate. The improvement level depends on the read depth, pedigree structure, 
pedigree size and the position the individual in the pedigree. Sometimes, sequencing the 
individuals in a family with moderate read depth gives more and better results than sequencing 
one individual with high read depth. It is better if we can sequence large families. When large 
families are not available, the simulation and real data show that sequencing a family with 7 
individuals of three generations has big improvement in variant calling accuracy. 
In family-base sequencing analysis, pedigree information data is usually very complex. One 
method cannot meet the requirements all the time. We implement four different methods in 
FamSeq to avoid these problems. We compared the difference among these four methods in 
Chapter 3. We focused on the application of GPU to improve the computing speed. When family 
size is relatively large, GPU has 10-fold improvement comparing to CPU. In next generation 
sequencing analysis, the computing tasks are usually homogeneous. It is very suitable for GPU 
since it has much more computing cores than CPU.  
In Chapter 4, we introduced another method to improve the germline mutation detection in 
next generation sequencing data. The new method used the Bayesian hierarchical model to 
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combine the data from multiple platforms to reduce variant calling error by using the information 
from other platforms when one platform failed. In the application of the methods in the two most 
popular sequencing platforms, variant calling error rate decreased about 25% percent when we 
have enough training data. This method can also be applied to the sequencing data generated from 
old platforms. We can use the old sequencing data with the new data to improve the variant 
calling accuracy. We can also combine the old sequencing data together to get the result has 
similar accuracy rate as the new data, when some individuals are sequenced multiple times by old 
platforms, such as NA12878. It will save a lot time and money without sequencing these 
individuals again.  
We also applied the pedigree information to estimate the TP53 mutation carrier probability. 
Comparing to the existing clinical criteria, our method, LFSpro, gives an estimation of probability 
instead of a binary result. With the probability, we can change the cut-off to balance the 
sensitivity and specificity. The de novo mutation plays an important role in Li-Fraumeny 
syndrome. We incorporated de novo mutation rate into the Mendelian risk prediction model and 
estimate the de novo mutation rate in two different data sets.  
 
6.2 Future Research  
A key character in Li-Fraumeni syndrome is multiple primary cancers. In LFSpro, we only 
consider the earliest primary cancer, which will lose a lot useful information. It partially 
explained the reason why LFSpro does not perform better than the Chompret criteria in adult 
sarcoma data set. Another reason is the penetrance used in LFSpro is estimated from the 
population in the United States, while the adult sarcoma data is collected in Australia. The 
penetrance might be very different between the two countries. To improve the performance of 
LFSpro, we should build a new model to consider multiple primary cancers. On the other hand, 
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we can collect more Li-Fraumeni syndrome family data from Australia and use these data to 
estimate the penetrance specific for Australia.  
We need training data with true variants to estimate the parameters to build the model 
combining the data sets form multiple platforms to call the variant with next generation 
sequencing data.  However, we cannot get training data for most data sets. It cost a lot of money 
and time to generate true variants in next generations sequencing data. In future, I will develop a 
method that does not need the training data for better application on the basis of current model. 
How to integrating different biology data together is a difficult and popular problem in 
biology research recently. The model we build to combine sequencing data from multiple 
platforms can be adapted to integrate different biology data. For example, we can predict cancer 
stage from gene expression and MRI image by calculating the posterior probability of Pr(Cancer 
Stage | Gene Expression, MRI image).  
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